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1CHAPTER 1. OVERVIEW
1.1 Thesis organization
The main theme of this thesis is to develop better diagnostics for pharmacokinetic mod-
els. It consists of two components: methodology and software. The methodology component
includes chapter 2, 3, and 6, focusing on diagnostic methods for population pharmacokinetic
models. The software component consists of chapter 4 and 5 and emphasizes two related
software: PKgraph and PKreport derived from methodology component.
Chapter 1 provides a general overview and research scope for this thesis. It covers expla-
nations of pharmacokinetic (PK) data, PK models, Population PK (PopPK) models, model
diagnostics, related software, and data used for examples in the thesis. Chapter 2 describes
methods to check model assumptions and goodness of ﬁt during model building. Two case
studies were utilized to illustrate these methods for exploration data analysis, goodness of ﬁt,
parameter and random eﬀects evaluation, structural model diagnostics, residual model diag-
nostics and covariate model diagnostics. Chapter 3 develops methods for diagnosing PopPK
models by visualizing resampling statistics. In this work, we adapt visual methods from mul-
tivariate analysis, parallel coordinate plots and multidimensional scaling. Chapter 4 describes
an R package, PKgraph, that was developed as part of this thesis. This software provides a
graphical user interface for PopPK model diagnosis. It also provides an integrated and com-
prehensive platform for exploration of PK data. Chapter 5 describes an R package, PKreport,
which is for automatic report generation, for checking model assumptions, visualizing data
and diagnosing models. Chapter 6 presents some preliminary work on covariate selection. We
explore the eﬀects of covariate correlation on covariate model building and compare perfor-
mance of three algorithms for covariate selection, including generalized additive model (GAM),
2gradient boosting and random forest. Finally, Chapter 7 gives conclusions and plans for future
work.
1.2 Pharmacokinetic data
Two data sets were used in this thesis are as follows.
1.2.1 Data set 1
This example, Theoph in NONMEM (Boeckmann et al., 1994), is from a study of the
pharmacokinetics of drug theophylline, which was used to treat asthma. This is a short-
duration study (about 24 hours) and only one dose per subject is given. There were 12 subjects
in this research, and each subject was measured 11 times post-dose. Table 1.1 describes the
variables in the data. Sample data for one subject are shown in Table 1.2.
Data variables Description
Subject unique ID for each subject
Time clock time (hour)
Wt weight (kilogram)
Dose dose of theophylline administered orally to the subject (mg/kg)
conc theophylline concentration in the sample (mg/L)
Table 1.1 Variable description for data set 1.
1.2.2 Data set 2
This is an example used to illustrate PK/PD modeling using NONMEM downloaded
at https://www.accp1.org/pharmacometrics/Datafile/CS1 IV1EST PAR.csv. There were
100 subjects, and each individual was sampled with 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8,
12, 16, 20, 24 hours post-dose. The variables are described in Table 1.3. Sample data for one
subject are shown in Table 1.4.
3Subject Wt Dose Time conc
1 79.6 4.02 0 0.74
1 79.6 4.02 0.25 2.84
1 79.6 4.02 0.57 6.57
1 79.6 4.02 1.12 10.5
1 79.6 4.02 2.02 9.66
1 79.6 4.02 3.82 8.58
1 79.6 4.02 5.1 8.36
1 79.6 4.02 7.03 7.47
1 79.6 4.02 9.05 6.89
1 79.6 4.02 12.12 5.94
1 79.6 4.02 24.37 3.28
Table 1.2 Sample data for subject 1 from data set 1.
Data variables Description
TIME Time (hour)
DV/CONC Dependant variable (concentration in plasma, ug/ml)
AMT Dose (mg)
MDV Missing dependant variable (MDV = 1 when DV = 0 or missing(.))
SCR Serum creatinine
CLCR Creatinine clearance (ml/min)
AGE Age (year)
WT Body weight (kilogram)
ISM Gender (0 female, 1 male)
Table 1.3 Variable description for data set 2
4CID TIME CONC AMT DOSE MDV AGE WT SCR ISM CLCR
1 0 0 100 100 1 34.823 38.212 1.1129 0 42.635
1 0.25 13.026 0 100 0 34.823 38.212 1.1129 0 42.635
1 0.5 14.984 0 100 0 34.823 38.212 1.1129 0 42.635
1 0.75 14.16 0 100 0 34.823 38.212 1.1129 0 42.635
1 1 19.316 0 100 0 34.823 38.212 1.1129 0 42.635
1 1.5 13.146 0 100 0 34.823 38.212 1.1129 0 42.635
1 2 12.921 0 100 0 34.823 38.212 1.1129 0 42.635
1 2.5 8.485 0 100 0 34.823 38.212 1.1129 0 42.635
1 3 16.437 0 100 0 34.823 38.212 1.1129 0 42.635
1 4 10.724 0 100 0 34.823 38.212 1.1129 0 42.635
1 6 8.7352 0 100 0 34.823 38.212 1.1129 0 42.635
1 8 7.697 0 100 0 34.823 38.212 1.1129 0 42.635
1 12 4.479 0 100 0 34.823 38.212 1.1129 0 42.635
1 16 2.4183 0 100 0 34.823 38.212 1.1129 0 42.635
1 20 4.7586 0 100 0 34.823 38.212 1.1129 0 42.635
1 24 2.3655 0 100 0 34.823 38.212 1.1129 0 42.635
Table 1.4 Sample data for subject 1 from data set 2.
1.3 Pharmacokinetic models
The application of PK modeling to drug development has grown exponentially (Sheiner
and Steimer, 2000; Csajka and Verotta, 2006). Currently, the PK model is an important tool
in drug development. In pre-clinical studies, it helps interpret data from animals to prepare
for testing in humans; in clinical testing, it eﬃciently quantiﬁes the inter-variability and intra-
variability even with very few measurements per subject (Prez-Urizar et al., 2000).
PK models were ﬁrst introduced by Teorell (1937), in order to explain drug absorption, dis-
tribution, and elimination. He proposed compartments to separate organs and tissues, linked
by ﬁrst order kinetic rate. Since then, the PK model has been accepted as the main way to
analyze dose-response relationship. There are several kinds of models: empirical, physiologi-
cally based and compartmentally based models (Shargel et al., 2004). This thesis focuses on
compartmentally based model, which considers human body as a collection of compartments.
Let’s look at a simple one-compartment model with bolus intravenous injection (Figure 1.1)
described in Welling (1997),
5Figure 1.1 One compartment model with bolus intravenous injection. 퐴:
the amount of drug in the body. 퐴 = 퐶 ∗ 푉 , where 퐶 is the
concentration of drug in body ﬂuids and 푉 is the drug distri-
bution volume; 푘푒푙: the elimination rate constant, i.e., the ﬁrst
order rate constant for drug elimination from the body.
Utilizing a diﬀerential equation, we can get,
푑퐴
푑푡
= −푘푒푙퐴 (1.1)
where t is time. Integrating, we obtain,
푙푛퐴− 푙푛퐴0 = −푘푒푙푡 (1.2)
and then,
푒
푙푛( 퐴
퐴0
)
= 푒−푘푒푙푡 (1.3)
퐴 = 퐴0푒
−푘푒푙푡 (1.4)
Finally, we can translate the amount of drug in the body (A) to the concentration of drug
(C) by dividing by the volume of distribution (V),
6퐶 = 퐶0푒
−푘푒푙푡 (1.5)
Another example I would like to explain here is the two-compartment open model with
rapid intravenous injection (Figure 1.2) discussed in Welling (1997) and Bourne (2010).
Figure 1.2 Two compartment model with rapid intravenous injection. 퐴1:
the amount of drug in the central compartment. 퐴1 = 퐶1 ∗ 푉1,
where 퐶1 is the concentration of drug in the central compart-
ment and 푉1 is the drug distribution volume in the central com-
partment; 퐴2: the amount of drug in the peripheral compart-
ment; 푘푒푙: the elimination rate constant, i.e., the ﬁrst order rate
constant for drug elimination from the body; 푘12: the rate con-
stant for transfer of drug from compartment 1 to compartment
2; 푘21: the rate constant for transfer of drug from compartment
2 to compartment 1.
It is described by the following equations,
푑퐴1
푑푡
= 푘21퐴2 − 푘12퐴1 − 푘푒푙퐴1 (1.6)
푑퐴2
푑푡
= 푘12퐴1 − 푘21퐴2 (1.7)
7After solving these equations as described in Bourne (2010), we get the ﬁnal equation for
the central compartment as follows,
퐶1 = 퐴푒
−훼푡 +퐵푒−훽푡 (1.8)
where,
퐴 =
퐷(푘21 − 훼)
푉1(훼− 훽) (1.9)
퐵 =
퐷(푘21 − 훽)
푉1(훼− 훽) (1.10)
훼 =
1
2
[(푘12 + 푘21 + 푘푒푙) +
√
(푘12 + 푘21 + 푘푒푙)2 − 4푘21푘푒푙] (1.11)
훽 =
1
2
[(푘12 + 푘21 + 푘푒푙)−
√
(푘12 + 푘21 + 푘푒푙)2 − 4푘21푘푒푙] (1.12)
1.4 Population pharmacokinetic (PopPK) models
The PopPK model (Sheiner et al., 1972, 1977) extends the PK model to incorporate in-
dividual variability. The PopPK model can quantify the dose-response relationship with only
a few measurements per subjects, and incorporate related clinical data from other resources,
such as age and weight of the subject. It is superior to the PK model, which can only ade-
quately describe a homogeneous population with many observations. Developing the PopPK
model has become the main research endeavor in pharmacokinetics in this decade (Samara and
Granneman, 1997; Minto and Schnider, 1998; Sun et al., 1999; Ette et al., 2004). Many new
algorithms have been developed: two-stage, nonlinear mixed eﬀect models, and Bayesian hier-
archical model (Bauer et al., 2007). In regards to the signiﬁcance of PopPK modeling in drug
development, the Federal Drug Administration (FDA) issued a guideline that analysts use this
model in order to standardize the drug development process (Food and Drug Administration,
1999).
8The PopPK model is developed based on nonlinear mixed eﬀects model, and the main goals
of this model are twofold: 1) model the relationship between concentration and dose dependent
on the covariates; 2) estimate mechanic parameters and related variability. The random eﬀects
component extends the model to describe not only intervariability (between subjects), but also
intravariability (within subjects).
1.4.1 General formulation for PopPK models
Let’s deﬁne the general formulation for PopPK models (Pinheiro and Bates, 2009) :
Intravariability level,
푦푖푗 = 푓(푥푖푗 ;휓푖) + 휖푖푗 푖 = 1, 2, ..,푀 ; 푗 = 1, 2, ..., 푁푖; (1.13)
where 푖 is the subject ID; 푗 is the number of samples; 푥푖푗 is a vector of known quantities, such
as dose, time; 휓푖 is a vector of parameters, such as clearance, volume of distribution; 휖푖푗 is the
measurement error; 푦푖푗 is the observed response.
Intervariability level,
휓푖 = 푔(휃, 푧푖) + 휂푖 휂푖 ∼ 푁(0,Ψ) (1.14)
where 휓푖 is a vector of parameters for 푖th subject, such as clearance, volume of distribution;
휃 is the population parameter; 푧푖 is the vector of individual covariates, such as weight, age,
gender; 휂푖 is the vector of random eﬀects for 푖th subject; Ψ is the variance-covariate matrix.
Covariates can be divided into two categories: 1) intrinsic factors: age, weight, height and
race; These factors do not change during study. 2) extrinsic factors: dose, smoking status, etc.
These factors may change during study.
Now let’s consider a real example and write these models in the context of pharmacokinetics.
We use two parameters (CL and V), one covariate (WT) and proportional residual error model.
Intravariability level,
푦푖푗 = 푓(푑표푠푒; 푡푖푗 ;훽푛)[1 + 휖] (1.15)
9where dose is the initial dose; t is time; 훽푛 is a vector of 푛 mechanic parameters, such as
clearance and volume of distribution.
Intervariability level,
푉푖 = 푉 (푊푇/70)푒
휂1 (1.16)
퐶퐿푖 = 퐶퐿(퐴퐺퐸)푒
휂2 (1.17)
1.4.2 PopPK model building
Ette and Ludden (1995) explained this process as ﬁve steps: 1) build structural PK model;
2) diagnose the distribution of random eﬀects; 3) screen covariates; 4) build covariate model;
5) evaluate parameter estimates.
Of these ﬁve steps, determining the covariates is a challenge. The general approach is
to regress covariates against the estimated parameters to detect any patterns between them.
Mandema et al. (1992) applied the generalized additive model to covariate model selection
based on ﬁrst extracting empirical Bayes estimates. Semmar et al. (2005) applied hierarchical
cluster analysis to combine single covariate. By building a multivariate categorical covariate,
they achieved a three-cluster model with better performance than basic model.
1.5 Model diagnostics
Model diagnostics is also known as “model evaluation” (Kutner et al., 2004), “model as-
sessment” (Cook, 1998) and “model appropriateness” (Ette et al., 2003; Brendel et al., 2007).
Cook and Weisberg (1994) claimed that model diagnostics help to disprove model with the
information obtained from data. In this thesis, I focus on two diagnostic approaches: checking
PopPK model assumptions and goodness of ﬁt, and examining resampling statistics.
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1.5.1 Checking assumptions and goodness of ﬁt for population pharmacokinetic
models
In this section, we would like to cover goodness of ﬁt plots, evaluation of parameter un-
certainty, and diagnostics for multiple submodels (structural model, residual error model, and
covariate model).
Goodness of ﬁt (GOF) is one important statistical tool in assessing models. Especially
because some numerical metrics may be misleading (Cook and Weisberg, 1994), the graphic
characteristics of GOF discover the true pattern and evaluate models eﬃciently. GOF plots
dwell on scatter plot of predictions, observations and other related variables to check model
ﬁtness, numerical model assumptions, and qualiﬁcation of variability. We explore GOF plots
according to Karlsson et al. (1998), Wade et al. (2005) and Brendel et al. (2006), including
population predictions (PRED) versus observations or time, weighted residuals (WRES) versus
PRED or time, individual predictions (IPRED) versus observations or time.
Uncertainty of parameter is one of the main model assessments. The reliability of parameter
not only aﬀects ﬁnal prediction, but also helps to determine model robustness. Generally, the
distribution of parameters is investigated with regards to standard error (SE) and conﬁdence
interval (CI). In addition, the linear relationship among parameters is also explored to detect
associations.
PopPK models utilize many submodels. These submodels contribute to model complexity
and it is essential to diagnose these submodels respectively to detect any hidden patterns.
Karlsson et al. (1998) explained how to check assumptions for covariate and statistical sub-
models. Later, Wilkins extended to a software called Census (Wilkins, 2005a), including the
following diagnostics for submodels:
∙ Structural model diagnostics: PRED vs DV ∣ IDV, IPRED vs DV ∣ IDV, WRES vs IDV,
WRES vs PRED, PRED vs DV ∣ Covariates
∙ Residual model diagnostics: Distribution of WRES, individual distribution of WRES,
absolute weighted residuals (∣WRES∣) vs PRED, ∣WRES∣ vs PRED ∣ Covariates, ∣WRES∣
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vs IPRED ∣ Covariates, and autocorrelation of WRES
∙ Covariate model diagnostics: scatterplot matrix of covariates, parameters vs covariates,
ETAs vs covariates, WRES vs covariates.
In this thesis, we will follow the same guideline for submodel diagnostics.
1.5.2 Diagnosing resampling statistics for population pharmacokinetic modeling
Resampling techniques have been widely applied to PopPK modeling to assess the uncer-
tainty of parameters, detect inﬂuential observations and test hypothesis (Bruno et al., 1996;
Ette, 1997; Ishibashi et al., 2003; Rigby-Jones et al., 2005; Takama et al., 2006; Fasanmade
et al., 2009; Marier et al., 2010). Generally, hundreds or thousands of resampling are gener-
ated for speciﬁc research goals. Users will only investigate the numeric summary related to the
resampling methods rather than extract detailed information from those resampling data sets.
However, The PopPK model employs complex statistical models, and it will be informative to
explore these resampling data sets and gain deep understanding of the data and model. At
this time, there is no research done in this ﬁeld.
In this thesis, we demonstrate how to visualize multidimensional resampling data based on
the framework of interactive graphics. Diverse visualization techniques, including histogram,
parallel coordinate plots, and multidimensional scaling are implemented to explore the data
structure. By linking these visualization techniques through interactive graphics, we can ex-
plore these multidimensional data from an integrated and systematical perspective. To our
knowledge, this is the ﬁrst attempt in pharmacokinetic ﬁeld to incorporate interactive graphics
for data analysis.
1.6 Software
PK data focus on dose-response relationship, and because of time constraints, ethnic issues
and budget, these kinds of data have the following unique features: unbalanced design, sparse
data, and non-optimal design (Dartois et al., 2007). Nonlinear mixed eﬀects models have been
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employed to analyze these PK data for a few decades. Currently, there are many software
available for PopPK modeling. In this section, I will focus on four main software tools (NON-
MEM, Monolix, R nlme package, and SAS NLMIX procedure) in this ﬁeld. The ﬁrst two are
speciﬁcally designed for PopPK models, while the other two aims to analyze nonlinear mixed
eﬀects models and provide broader perspective not limited to PopPK models. In the following
paragraph, I will review these software and provide some background with emphasize on the
ﬁrst two tools.
1.6.1 NONMEM
NONMEM was the ﬁrst program for PopPK model, which was developed by Beal and
Sheiner (1980) in University of California, San Francisco. The original goal was to handle
sparse data from clinical trials. It was recognized as the most widely used software in PK
model and has been evolving until now (current version is NONMEM 7.0).
NONMEM estimation method is based on least squares type criterion, consisting ordinary
least square criterion and weighted least squares criterion. There are two estimation methods
explored in NONMEM, ﬁrst-order approximation (FO) and ﬁrst-order conditional estimation
(FOCE). FO method was the ﬁrst approximation approach taken by NONMEM (NONMEM
user guide), and still available in these days. However, because of estimation bias, the ﬁrst order
condition estimation (FOCE) was developed to address this question. FOCE implemented an
alternative method to calculate individual random eﬀects based on condition, the approach that
incorporates interaction between random eﬀects and statistical errors. In addition, NONMEM
provides additional options for estimation, including centering and hybrid to deal with various
data sets and diversiﬁed models.
NONMEM is developed in Fortran, and as a result, all model diagnostics are explored in a
comparatively simple way with regards to the lack of graphical ability. NONMEM diagnostic
tools consist of DV versus PRED plot, residual plots, index plots of residuals, plot of WRES
versus independent variable, and goodness of ﬁt plots.
Though NONMEM is leading software in the PopPK ﬁeld, the accuracy of NONMEM
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requires further improvement, especially for parameter estimation and variance approximation.
This inaccuracy comes inherently from the three approximation approaches implemented in
NONMEM: FO, FOCE and Laplacian.
1.6.2 Monolix
In 2003, Monolix is developed as a Matlab program (The Monolix group, 2010). It em-
ployed an alternative approach to calculate maximum likelihood estimators based on SAEM
algorithms. This algorithm applies stochastic approximation to standard EM algorithms and
includes three steps: simulation step, stochastic approximation and maximization step (Mono-
lix user guide). During each iteration, the random parameters are simulated from conditional
distribution in E step; the parameters are updated until SAME converges to the local or global
maximum likelihood. To perform simulation step directly, MCMC is combined with SAME
algorithm to take advantage of Hastings-Metropolis algorithm. In addition, since global max-
imum is a big challenge to reach, Monolix implements simulated annealing to address this
question. By incorporating simulated annealing, SAME algorithm does not solely depend on
initial guess of parameters, and thus convergence to global maximum is improved.
Based on Matlab, Monolix provides user-friendly graphical interface, powerful and conve-
nient PK/PD model library, goodness of ﬁt plots, and a standard-alone non-matlab program.
In addition, C++ is utilized as a basic layer for complex ODE models to speed up calculation.
1.6.3 NLMIXED(SAS) and S/R nlme package
SAS NLMIXED procedure is available in SAS version 8.0 and higher, targeting nonlinear
mixed eﬀects model. This procedure implements two main approximation methods: ﬁrst-order
Taylor series and adaptive Gaussian quadrature for parameter estimation. Compared with
NONMEM, SAS NLMIXED procedure takes advantage of Monte Carlo simulation for integral
approximation to maximize likelihood, and thus achieves more accurate results. However, this
procedure aims at nonlinear mixed eﬀects model, not particularly for PK models, and it runs
more slowly.
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S/R nlme package was originally developed by Jose C. Pinheiro and Douglas M. Bates
(Pinheiro et al., 2009). It provides FOCE and Laplacian approximation methods. However,
like NLMIXED(SAS), it aims at nonlinear mixed eﬀects model, not particularly for PK models.
1.6.4 Other software
NONMEM and Monolix only provide limited functions for model validation. In recent
years, more software packages appeared to enrich NONMEM with diﬀerent features. For
example, PsN, a perl module, tries to grant NONMEM more external environment (Lindbom
et al., 2004). It not only oﬀers convenient tools for management, but also implements case
deletion diagnostics, bootstrap, and stochastic simulation for model validation. It can be
connected with NONMEM to extract parameter estimation from output ﬁles, subset data sets,
manage NONMEM runs, and perform additional model building procedure.
In 1999, Xpose was implemented to improve graphic abilities of NONMEM and auxiliary
analyses (Jonsson and Karlsson, 1999). It includes the following features: simplify document
production, create data set checkout plot and goodness of ﬁt plot, and compare diﬀerent
model graphically. In addition, generalized additive modeling (GAM), bootstrap and tree-
based modeling are incorporated into package to assist covariate model building. Census was
later developed to function as the graphical user interface for Xpose as a management and
graphical platform.
PsN, Xpose and Census were developed with speciﬁc functions and separate components,
and these three software “form a tightly-knit web of open-source, freely-available applications
for NONMEM modelling and simulation” (http://xpose.sourceforge.net/links.php).
In addition, there are a lot of other tools designed for PopPK analysis. For example,
NONMEMMory, a management tool, aims to create user-friendly platform to control sum-
mary, comparison and modeling (Wilkins, 2005b). Also, with the exponential usage of R
platform, many R packages have been written for NONMEM. PKﬁt, an R package, han-
dles PK/pharmacodynamic models including following features: noncompartmental analysis,
compartmental analysis, nonlinear kinetic process, drug absorption, pharmacodynamic data
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modeling, simultaneous ﬁtting and user-deﬁned library (Farenc et al., 2000). Metrum Insti-
tute Open-Source tools are developed by Metrum Institute, consisting of NUMQual, MIfuns,
bugsParallel, bugsPKPDmodelLibrary and SASxport (Metrum Institute, 2010). PKbugs, a
program based on BUGs, is available for Bayesian data analysis (Lun, 2010).
1.7 Research problem and scope
Biological problems often involve ﬁtting nonlinear models to data. In pharmacokinetics,
analysts study a subject’s response to drug doses, which will typically follow a quick increase
in concentration as the drug circulates through the body, and a gradual nonlinear decrease
as it is processed and eliminated. These models are diagnosed with the help of experimental
data.
Some special modeling software exists for most of these problems, for example NONMEM,
Monolix. General modeling software can also be used, such as PROC NLMIX in SAS and the
package nlme in S/R. A common problem is that these tools do not provide ways to adequately
diagnose the model ﬁt. The FDA is encouraging new approaches to model diagnosis.
This thesis addresses this gap, with the following contributions: 1) developing methods and
tools to check the model assumptions and goodness of ﬁt for PopPK models; 2) visualizing
resampling statistics for PopPK models; 3) implementing interactive graphics for PopPK model
diagnostics; 4) exploring the eﬀects of covariate correlation on PopPK covariate modeling.
16
CHAPTER 2. CASE STUDIES ILLUSTRATING THE USE OF
GRAPHICS IN POPULATION PHARMACOKINETIC MODEL
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Abstract
The more complex a statistical model is the more diﬃculty it can be to diagnose the ﬁt.
Population pharmacokinetic (PopPK) models are complex mixed eﬀects models, ﬁtting a non-
linear trend and individual characteristics. Graphics plays an important role in PopPK model
building by exploring for hidden structure among data before modeling, detecting anomalies
during modeling, and validating results after modeling. In this paper two case studies are
used to demonstrate these graphics for PopPK model building, focusing on these aspects, ex-
ploratory data analysis, goodness of ﬁt, parameter and random eﬀects evaluation, structural
model diagnostics, residual model diagnostics and covariate model diagnostics. Interactive
graphics are also illustrated. The approaches described in this paper enrich PopPK model
building and provide systematic and comprehensive view of pharmacokinetic data.
2.1 Introduction
The application of population pharmacokinetic (PopPK) modeling in the drug development
has grown in this decade because it can handle unbalanced design and sparse data (Samara
17
and Granneman, 1997; Sun et al., 1999; Ette et al., 2004). However, this advantage does not
come without a cost. The complexity of model brings challenges in diagnosing the model ﬁt.
Graphics play an important role here, helping to explore for hidden structure among data
before modeling, detecting extremity during modeling, and validating results after modeling
(Cleveland, 1993; Karlsson et al., 1995; Ette and Ludden, 1995; Karlsson et al., 1998; Ette,
1998; Ette et al., 2001b; Petricoul et al., 2001; Brendel et al., 2006; Karlsson and Savic, 2007;
Ene I. Ette, 2007).
From the statistical perspective, Ette (1998) gives a comprehensive tutorial for the applica-
tion of graphics in PopPK modeling. He recommends making distribution plots, scatter plots,
residual plots, partial residual plots, pairs plots, conditional plot, contour plots and star plots.
From a model perspective Karlsson et al. (1998) proposes graphics to investigate assumptions
required for the PopPK model. In this paper, the authors described 22 assumptions for vari-
ous situations during the model development. By going through each stage of model building
process with graphics, Bonate (2005) demonstrates how to facilitate modeling building with
graphics, especially with the real PopPK examples.
This paper uses these approaches in the case studies and extends the methods to include
interactive graphics. Interactive graphics has a long history in statistics and has proved to
be powerful tool for exploring the data structure and relationship, and diagnosing models
(McDonald, 1982; Cook and Weisberg, 1994; Jog and Shneiderman, 1995; Swayne and Buja,
1998; Unwin et al., 2006; Cook et al., 2007). Jonsson et al. (2007) claimed that it would be a
potential tool for pharmacokinetic data analysis. In this research, we cover general framework
of pharmacokinetic diagnostics, including exploring data and checking model assumptions by
analyzing two case studies. Interactive graphics is also explored in one case study.
2.2 Methods
Many authors (Ette, 1998; Karlsson et al., 1998; Bonate, 2005) had done extensively re-
search in model assumption testing, and we followed these guidelines to automatically perform
the following assumption testing: 1) exploratory data analysis; 2) goodness of ﬁt plots; 3)
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parameter and random eﬀects evaluation; 4) structural model diagnostics; 5) residual model
diagnostics; 6) covariate model diagnostics. We used the R packages lattice (Sarkar, 2008), gg-
plot2 (Wickham, 2009) for static graphics, and rggobi (Temple Lang et al., 2009) for interactive
graphics.
2.2.1 Exploratory data analysis
Dose history, covariate information, and diverse clinical trials for same purpose should be
checked for correctness and accuracy before analyzing models, and data structure should be
investigated to screen hidden patterns, outliers and extreme observations linked to individuals
for further analysis. Currently, histogram and scatter plot combined with conditional plot were
implemented to help achieve these goals. Karlsson emphasized the plots for each patient ID
versus each variable in the data ﬁle (Karlsson et al., 1998), and Ette pointed out exploratory
examination of concentration, distribution and correlations between covariates (Ette, 1998).
All of these guidelines were implemented in the case studies.
In addition, we examined a unique technology called interactive graphics. This technique
is a powerful tool for data visualization and has very unique feature to link diverse datasets.
Cook et al. (2007) showed interesting examples for data mining. In this work, we used R
package: rggobi to explore the data pattern and structures.
2.2.2 Goodness of ﬁt plots
Goodness of ﬁt plots play a key role in checking model ﬁtting. These kinds of plots give
an overall perspective of model performance, including scatter plot for concentration versus
PRED, concentration versus IPRED, PRED versus time and IPRED versus time (European
Medicines Agency, 2007). Most reports submitted to FDA are required to explain response
from each patient, and individual plots for concentration/PRED/IPRED versus time are of
great importance.
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2.2.3 Evaluate parameters and random eﬀects
Generally, there are assumptions for distribution of parameters during modeling process.
The histogram was utilized to check this distribution. In addition, the correlation of param-
eters has signiﬁcant eﬀect on modeling performance, and it was checked by scatter plots or a
scatterplot matrix. The assumptions for random eﬀects were also tested for distribution and
correlation by histogram, scatter plots or a scatterplot matrix.
2.2.4 Diagnose structural models
Structural model describes the model without the covariates. In practice, there are three
popular structural models for use, including 1-, 2-, and 3-compartment models with diﬀerent
absorption models. After determining structural models, we can further build covariate models
by incorporating right covariates. Structural model was diagnosed by PRED versus concen-
tration conditioned on time, IPRED versus concentration conditioned on time, WRES versus
time, WRES versus PRED, PRED versus concentration conditioned on covariates, IPRED
versus concentration conditioned on covariates.
2.2.5 Diagnose residual error models
Residual model deals with random and unexplained variability (휖 in the following function)
due to model misspeciﬁcation, assay errors, dosing history errors, etc.
푦푖푗 = 푓(푑표푠푒; 푡푖푗 ;훽푡) + 휖 (2.1)
Generally, PopPK model consists of the following common residual models:
∙ additive error
푦푖푗 = 푓(푑표푠푒; 푡푖푗 ;훽푡) + 휖 (2.2)
∙ proportional error
푦푖푗 = 푓(푑표푠푒; 푡푖푗 ;훽푡)(1 + 휖) (2.3)
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∙ exponential error
푦푖푗 = 푓(푑표푠푒; 푡푖푗 ;훽푡)푒
휖 (2.4)
∙ combined additive and proportional error
푦푖푗 = 푓(푑표푠푒; 푡푖푗 ;훽푡)(1 + 휖1) + 휖2 (2.5)
Two assumptions (Karlsson et al., 1998) are related to this submodel: 1) homoscedastic
variability; 2) symmetrically distributed residuals. To test these assumptions, we applied the
following techniques: 1) histogram for distributions of WRES; 2) histogram for individual
distribution of WRES; 3) scatterplot of ∣WRES∣ versus PRED to check the shape of residual;
4) scatterplot of ∣WRES∣ versus PRED conditioned on covariates to screen the covariate eﬀects;
5) autocorrelation of WRES.
2.2.6 Diagnose covariate models
In general, covariate models study how to incorporate covariates into the model. By linking
subject-speciﬁc characteristics with model parameters, we can identify right covariates for
model. Parameters, ETA and WRES are of great use to help screen proper covariates. We
utilized the following methods to check covariate models: 1) scatter plot for parameters versus
covariates, ETAs versus covariates, WRES versus covariates; 2) scatterplot matrix of covariates.
2.3 Case study 1
2.3.1 Introduction
The data is from a study of the pharmacokinetics of drug theophylline, which was used to
treat asthma. It is data set 1 described in Chapter 1.
The primary question is: “How does theophylline concentration in plasma change with
time?”. Second or additional questions: “How does covariate, dose, aﬀect drug concentra-
tion?”.
Since there are only 12 subjects in this research, we will assume normality for within-group
errors.
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2.3.2 Analysis
2.3.2.1 Data restructuring:
Dose, and weight can be considered as subject-speciﬁc variables since it is same for each
subject, and concentration is response variable, which changes with measured time. As a
result, we split these four variables into two separate groups: subject-speciﬁc variable and
time-dependent variable.
2.3.2.2 Summary statistics:
To summary subject-speciﬁc variables such as dose, and weight, histogram or dot plot is
proper to view counts for each subject. Scatter plot facilitates users to identify relationship
or pattern between variables. Line plot or time plot can easily show how the concentration
changes with time, including minimum, maximum, and trend.
Subject-speciﬁc variables: Dose and Weight Dose for all subjects is between 3 and
6 (Table 2.1 and Figure 2.1) and weight is between 50 and 90 (Table 2.2 and Figure 2.2). Most
subjects has dose amount between 4.5 and 5 and weight between 60 and 80. From scatter plot
(Figure 2.3), there is a negative linear relationship between dose and weight.
Subject Dose
1 4.02
2 4.40
3 4.53
4 4.40
5 5.86
6 4.00
7 4.95
8 4.53
9 3.10
10 5.50
11 4.92
12 5.3
Table 2.1 Dose amount for each subject. The minimum amount is 3.10 for
subject 9, and the maximum amount is 5.86 for subject 5.
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Figure 2.1 Histogram of dose. Doses range between 3 and 6 mg/kg.
Time-dependent variable: concentration Concentration was measured between 0 to
24 hours with most measurements early and one measurements later near 24 hours (Table 2.3,
Table 2.4 and Figure 2.4). Figure 2.5 shows two peaks for the concentration: one around 0
and the other between 4 and 8. Figure 2.6 demonstrates a negative linear association between
concentration and weight, which is surprising. Figure 2.7 shows the time series of concentration
for all subjects.
2.3.3 Model ﬁtting
2.3.3.1 Observed concentration versus time
Figure 2.7 shows concentration by time separately for each subject, spiking quickly and
declining slowly. Figure 2.8 is ordered by maximum concentration, while Figure 2.9 is ordered
by time reaching peak, with decreasing order respectively. Subject 6 has lowest peak value,
and subject 5 has highest peak value.
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Figure 2.2 Histogram of weight in kilograms.
2.3.3.2 First-order Two Compartment Model
For this data set, ﬁrst-order two compartment model was utilized to analyze the data set
as most literature used this model for pharmacokinetics. The equation is as follows:
푐표푛푐 = 퐷표푠푒 푒휑1푖+휑2푖−휑3푖
푒−푒휑1푖푇 푖푚푒 − 푒−푒휑2푖푇 푖푚푒
푒휑2푖 − 푒휑1푖 + 휖푖푗 푖 = 1, ...,푀, 푗 = 1, ..., 푛푖
휑푙푖 = 퐴푖훽 +퐵푖푏푖 푏푖 ∼ 푁(0,Ψ) 푙 = 1, 2, 3
In this model, there are three nonlinear parameters, 휑1푖(lke), 휑2푖(lka), and 휑3푖(lCl), ranging
from 0 to positive inﬁnity:
∙ 휑1푖(lke): a numeric parameter representing the natural logarithm of the elimination rate
constant.
∙ 휑2푖(lka): a numeric parameter representing the natural logarithm of the absorption rate
constant.
∙ 휑3푖(lCl): a numeric parameter representing the natural logarithm of the clearance.
∙ 푖: patient ID.
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Subject Weight
1 79.6
2 72.4
3 70.5
4 72.7
5 54.6
6 80.0
7 64.6
8 70.5
9 86.4
10 58.2
11 65.0
12 60.5
Table 2.2 Weight for each subject. The minimum weight is 54.6, and the
maximum weight is 84.6.
∙ 푗: number of sampling.
∙ 훽: a vector of ﬁxed eﬀects.
∙ 푏푖: a vector of random eﬀects for ith group.
∙ 퐴푖, 퐵푖: are of appropriate dimensions and depend on the group and possibly on the
values of some covariates at the jth observation.
∙ Ψ: variance-covariance matrix.
Figure 2.10 - Figure 2.11 shows several curves generated by this function, with four param-
eters, Dose (initial dose), lke, lka, lCl, three ﬁxed and the fourth changing, respectively.
2.3.3.3 Fit the model
R package: nlme was used to ﬁt the ﬁrst-order two compartment model. The summary
about ﬁtting is shown in Table 2.5 and Table 2.6.
The equation with ﬁtted parameter values (lke: -2.45; lka: 0.47; lCl: -3.23) is as follows,
푐표푛푐 = 퐷표푠푒 푒−2.45+0.47+3.23
푒−푒−2.45푇 푖푚푒 − 푒−푒0.47푇 푖푚푒
푒0.47 − 푒−2.45
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Figure 2.3 Scatterplot of Dose and Weight. Dose has mg/kg unit, which
comes from total drug amount divided by weight.
Why does ﬁxed eﬀects part of the model ﬁt poorly for some subjects?
1. The dose is universally related to weight (Figure 2.3): heavier subjects get lower dose
(interesting!). Subjects 1, 9 are two of the heavier patients, and they get lower dose.
2. Weight may also have eﬀect on the ﬁtting. In Figure 2.3, it shows that there is a negative
relationship between dose and weight.
3. For subject 1, 7 and 9, it is diﬃcult to explain with variables available why the model
ﬁts poorly (Figure 2.15). It may suggest that we should include more covariates into
research, such as age, sex, etc.
Diﬀerence between ﬁxed eﬀects (Figure 2.15) and mixed eﬀects (Figure 2.16)
1. Fixed eﬀects for subject 6, 7, 8, 11 overestimated the observed value, while those for
subject 1, 5, 9 underestimated the observed value.
2. Mixed eﬀects for subject 5 and 9 underestimated the observed values. All mixed eﬀects
(ﬁtted values) are less than the observed values.
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Figure 2.4 Time histogram. Almost all concentration data were measured
between 0 and 15 hours, except that one was measured around
24 hours after single dose.
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Figure 2.5 Concentration histogram. There are two peaks, one around 0,
and the other between 4 and 7.
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Subject min Q1 Median mean Q3 max
1 0.000 0.845 3.820 5.950 8.040 24.370
2 0.000 0.760 3.500 5.869 8.015 24.300
3 0.000 0.800 3.620 5.907 8.035 24.170
4 0.000 0.835 3.500 5.940 8.020 24.650
5 0.000 0.760 3.500 5.894 8.060 24.350
6 0.000 0.865 3.570 5.888 8.110 23.850
7 0.000 0.760 3.480 5.865 7.990 24.220
8 0.000 0.750 3.530 5.890 8.110 24.120
9 0.000 0.840 3.530 5.868 7.985 24.430
10 0.000 0.895 3.550 5.915 8.230 23.700
11 0.000 0.740 3.600 5.872 8.030 24.080
12 0.000 0.750 3.520 5.876 8.050 24.150
Table 2.3 Time summary for each subject.
3. Subject 1 and 9 have biggest residuals for ﬁxed eﬀects (Figure 2.13). For subject 5, it
is interesting that the model for subject 5 ﬁts better with ﬁxed eﬀect than with mixed
eﬀect.
4. Deviance residual has decreased from 285.34 (ﬁxed eﬀect) to 55.15 (mixed eﬀect). Fig-
ure 2.16 claims similar results: ﬁtting with mixed eﬀect is much better than ﬁtting with
ﬁxed eﬀect.
2.3.3.4 Residual versus Time
The residual is distributed randomly in Figure 2.14. Some data may be outliers, but since
there are only 11 measured data for each subject, it should be proper for this analysis.
2.3.3.5 Fixed eﬀects versus concentration
For subject 6, 7, 8, and 11, the values of ﬁxed eﬀects are more than observed value;
for subject 9, and 1, the values of ﬁxed eﬀects are less than observed value (Figure 2.15).
Fixed eﬀects for subject 6 and 11 overestimates lag of curve, while those for subject 10 and 1
underestimates tail.
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Subject mean max sd
1 6.43 10.5 3.03
2 4.82 8.33 3.03
3 5.08 8.2 2.68
4 4.94 8.6 2.92
5 5.78 11.4 3.54
6 3.52 6.44 2.18
7 3.91 7.09 2.49
8 4.27 7.56 2.46
9 4.89 9.03 2.72
10 5.93 10.21 3.05
11 4.51 8 2.55
12 5.41 9.75 3.50
Table 2.4 Concentration summary for each subject.
Parameters Value Std.Error DF t-value p-value
lke -2.46 0.05 118 -46.77 0.00
lka 0.47 0.20 118 2.34 0.02
lCl -3.23 0.06 118 -53.78 0.00
Table 2.5 Summary for nonlinear mixed-eﬀect model ﬁt by maximum like-
lihood.
2.3.4 Conclusion
Here is a summary of the main ﬁndings:
1. For all subjects, the concentration peaks quickly, around 1-2 hours, and then decrease
slowly.
2. Each subject responds diﬀerently: the peak concentration varies by subject, and the time
to peak diﬀers.
3. The mixed eﬀects model ﬁts better than the ﬁxed eﬀects model, reducing the deviance
more than 5-fold (285.3 to 55.2). This suggests subject to subject variation is important
and not well-modeled by the covariate weight. The mixed eﬀects model inadequately ﬁts
all the peaks - it’s always too low.
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Figure 2.6 Scatterplot for maximum concentration versus weight. There
is a negative linear relationship between weight and maximum
concentration for each subject.
AIC BIC logLik
368.05 388.23 -177.02
Table 2.6 AIC, BIC and logLik values.
4. Some surprising results are: Subjects 1 and 9 are seriously underﬁt by the ﬁxed eﬀects
model. This is not explained by the weight or dose, suggesting missing covariates, for
example, gender or age, might be needed. This is somewhat improved in the mixed
eﬀects model, perfectly for subject 1, but less so for subject 9. Subject 5 is also badly
underﬁt by the mixed eﬀects model.
2.4 Case study 2
2.4.1 General nonlinear mixed eﬀects model formulation
Model formulation:
푦푖푗 = 푓((휑푙푖, 휗푖푗) + 휖푖푗 푖 = 1, ...,푀, 푗 = 1, ..., 푛푖
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Figure 2.7 Time plot of concentration versus time for each subject. The
highest concentration peak is 11.4 for subject 5.
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Figure 2.8 Observed values versus time for each subject, ordered by max-
imum concentration.
휑푙푖 = 퐴푖훽 +퐵푖푏푖 푏푖 ∼ 푁(0,Ψ) 푙 = 1, ..., 푄
Parameters in the model:
∙ 푖: patient ID. 푗: number of sampling.
∙ 휑푙푖: a group-speciﬁc parameter.
∙ 휗푖푗 : a covariate vector.
∙ 휖푖푗 : normally distributed measurement error, a within-group error term.
∙ 훽: a vector of ﬁxed eﬀects.
∙ 푏푖: a vector of random eﬀects for ith group.
∙ 퐴푖, 퐵푖: are of appropriate dimensions and depend on the group and possibly on the
values of some covariates at the jth observation.
∙ Ψ: variance-covariance matrix.
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Figure 2.9 Observed values versus time for each subject, ordered by time
reaching maximum concentration.
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Figure 2.10 Left ﬁgure: Time plot for concentration with diﬀerent dose,
same parameter values, lke, lka, lCl; Right ﬁgure: Time plot
for concentration with diﬀerent lke, same parameter values,
dose, lka, lCl.
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Figure 2.11 Left ﬁgure: Time plot for concentration with diﬀerent lka,
same parameter values, dose, lke, lCl; Right ﬁgure: Time plot
for concentration with diﬀerent lCl, same parameter values,
dose, lke, lka.
2.4.2 One compartment model with zero order absorption and ﬁrst order elimi-
nation
This is an example used to illustrate PK/PD modeling with NONMEM. There are total
100 patients, and in this pilot study, only ﬁrst ten patients were sampled for demonstration.
We are interested in the concentration of the drug in the organism in response to the dose,
over time. Here’s the formulation for a one compartment model:
푦푖푗 = 퐷표푠푒
1
휑1푖
푒
− 휑2푖
휑1푖
푡
+ 휖푖푗 푖 = 1, ...,푀, 푗 = 1, ..., 푛푖
Parameters in the model:
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Figure 2.12 Mixed eﬀects model ﬁtted values (blue line) and observed con-
centration (black points) versus Time. Subjects 5 and 9 are
substantially underﬁt.
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Figure 2.13 Dot plot for maximum ﬁxed eﬀect by each subject.
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Figure 2.14 Time versus Residual.
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Figure 2.15 Fixed eﬀects (red line) and observed concentration (black
points) versus Time.
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Figure 2.16 Mixed eﬀects (blue line), ﬁxed eﬀects (red line), and observed
values (black points) versus Time.
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∙ 휑1푗 : V, volume of distribution
∙ 휑2푗 : CL, clearance of drug
∙ KE: CL/V, elimination rate.
Assumption for model ﬁtting:
∙ Random eﬀects are normally distributed with mean 0, and homogeneous variance 휂.
∙ Measurement error is normally distributed with mean 0, and homogeneous variance 휎.
2.4.3 Data description
The data is described as data set 2 in Chapter 1. Figure 2.18 - Figure 2.19 are plots of the
data. The time plot for 10 patients is shown in Figure 2.17.
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Figure 2.17 Time plots for concentration versus time, for patient 1 to pa-
tient 10.
2.4.4 Data analysis strategy
In this analysis, we follow these steps,
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Figure 2.18 Left ﬁgure: A few more male(1) patients than female(0) ones;
Right ﬁgure: Two diﬀerent dose amounts, 100mg and 250mg
have been given to the equal number of patients.
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Figure 2.19 Left ﬁgure: Most patients weigh between 20 to 80kg with
several very heavy patients around 100kg; Right ﬁgure: Age
ranges from 10 to 80.
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∙ Investigate the eﬀects of the parameter in the model.
∙ Fit the data with one compartment model using NONMEM (time is the explanatory
variable).
∙ Check diagnostic plots for models, and along with the covariates (weight, age, etc.).
∙ Incorporate additional covariates into the model.
∙ Evaluate the model with interactive graphics.
2.4.5 Parameters
In pharmacokinetics, clearance (CL) determines the area under the curve (AUC), V de-
termines the peak concentration (Welling, 1997). Figure 2.20 - Figure 2.21 show the curves
resulting from diﬀerent values of CL, V, and dose. Increasing the dose increases the initial
concentration, eﬀectively shifting the curve up. Increasing KE changes the shape of the curve
reducing the time for the drug to be removed, and increasing CL has a similar eﬀect, although
it is more moderate. Changing V has little eﬀect.
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Figure 2.20 Left ﬁgure: Time plot for concentration with diﬀerent dose,
same parameter values, CL, V; Right ﬁgure: Time plot for
concentration with diﬀerent KE (elimination rate), with same
dose.
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Figure 2.21 Left ﬁgure: Time plot for concentration with diﬀerent
CL(clearance), same parameter values, DOSE, V; Right ﬁg-
ure: Time plot for concentration with diﬀerent V(volume of
distribution), same parameter values, DOSE, CL.
2.4.6 Model ﬁtting, building and selection
2.4.6.1 Error model
Additive error model was used for this case study.
2.4.6.2 Parameters
After ﬁtted with NONMEM, we got CL and V as 0.356 and 8.59, respectively.
푦푖푗 = 퐷표푠푒
1
8.59
푒−
0.359
8.59
푡 + 휖푖푗 푖 = 1, ...,푀, 푗 = 1, ..., 푛푖
2.4.7 Diagnostic plots for model: mixed eﬀect and ﬁxed eﬀect
Plots for mixed eﬀects (IPRED), and ﬁxed eﬀects (PRED) versus time on the data are
utilized to verify the ﬁtting (Figure 2.22 and Figure 2.23). In Figure 2.23, blue line represents
mixed eﬀects, red line represents ﬁxed eﬀects, and black points represent observed values. In
addition, patients with ID 1-10 are selected to display the ﬁtting status.
The three patients (ID: 8, 4, 9) also have a short reaction to the drug and not ﬁtted well
by the ﬁxed eﬀects model. The mixed eﬀects model improves the ﬁt for these patients.
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Figure 2.22 Fixed eﬀects versus time with observed value (black points)
and ﬁxed eﬀect/population eﬀect (red line).
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Figure 2.23 Fixed eﬀects (red) and mixed eﬀects (blue) model versus con-
centration for each patient.
42
  0
 20
 40
 60
 80
100
120
  0  20  40  60  80 100 120
ll lll llllllll
ll ll lll lll lll
ll
ll
l lll lll ll
l
l
l
ll l
l ll
lllll
ll
lll lll l
l
l
lll
l
ll
ll
l
lll
l
ll
l
llllll l
l
l
l
ll
l l
l
l lll
l
ll l
l
l ll
l l
l
l lll
ll
ll l
l
l
llll
l l
ll
lllll ll
ll ll l
l
lll l
l
l lllll ll
l
l
ll ll
l
l
l
l
ll lll lll
l
l
l
l
l
l
lll
l lll ll
l
l
ll ll
l
l
l
llllll
l
l lll
l
l
l
l
ll lll l
l
l
l ll
l
l l
l ll
l
l
l lll ll
l
lll
ll
ll
l l
ll
l
l
l
l
lll ll
lll llll
llll ll l
l
ll
l
ll
ll ll
l
l
l ll
lll l
l ll l
l
ll l
l
l l ll l
l
l
ll
ll
l
l
llll
l
l
l
l
l
l
l l
l
l
ll lll l
l
lll lll
l
l
l
l ll
l l llll llllll ll ll llll
l
l
l
l lll l lll l
l
ll ll
l llll lllllll
llll ll
ll
ll lll llll lllll
l
lllll l
l
lll llll
l
l
l
l
l
lll
l
ll ll llll l
l l
l l
l
l
l l l
l
l
l
l
l
ll l
ll
ll
llll
l ll
lll
l
l
l
l
l
l
l
l
l l
l
l
lll
l l ll
l
ll lll lll
l
ll
Pr
ed
ict
ed
 C
on
ce
nt
ra
tio
n
Concentration
Figure 2.24 Fixed eﬀect (blue), and mixed eﬀect (black) versus concentra-
tion.
2.4.8 Diagnostic plots for model: residuals (RES) and weighted residuals (WRES)
Residuals are checked with the following plots,
∙ Concentration versus predicted concentration for ﬁxed and mixed eﬀects model (Fig-
ure 2.24).
∙ Residuals versus predicted values for ﬁxed and mixed eﬀects model (Figure 2.25).
For a good ﬁt, the points in plot of CONC vs IPRED should be on the line of identity, and
the points of RES vs TIME plot should be randomly distributed.
For this case study, ﬁxed eﬀect is far from that identity line, and highly biased (Figure 2.24).
Residual (RES) is not randomly distributed (Figure 2.25) and weighted residual (WRES) does
a better job.
2.4.9 Covariate relationship
For covariates, such as age, weight, and gender, etc., they partly enter the model by aﬀecting
the parameters. So to explore the relationship among these variables, we ﬁrst check whether
or not there is correlation.
In this model, clearance, CL, is the ﬁrst parameter. We ﬁnd that there is positive association
between the random eﬀect of CL and weight (Figure 2.26), but we don’t ﬁnd any association
43
−15
−10
 −5
  0
  5
 10
 15
 5 10 15 20
l
ll
l
ll
l
l
l l l
l l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l l
l
l
l
l l l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll l
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
R
an
do
m
 R
es
id
ua
ls
TIME
Figure 2.25 Time versus random residual. Random residual is not ran-
domly distributed.
between CL and age or gender. As an example, we incorporate weight as a covariate in the
model,
푦푖푗 = 퐷표푠푒
1
휑1푖
푒
− 휑2푖
휑1푖
푡
+ 휖푖푗 푖 = 1, ...,푀, 푗 = 1, ..., 푛푖
휑1푖 = 휑1
푊푇푖
70
푒휂1
We rerun NONMEM and got CL and V as 0.905 and 9.76 respectively.
2.4.10 Basic diagnostics with interactive graphics
Figure 2.27 shows the data loaded into an interactive graphics style. The ﬁve plots are as
follows,
∙ Dose histogram (bottom left): high peaks (orange) are mostly from high dose.
∙ Weight histogram (bottom center): high peaks (orange) are mostly from light weight;
while low peaks (yellow) are mainly from heavy weight.
∙ Age histogram (Up center): there is no obvious diﬀerence in age for peaks.
∙ Time plot (Up right) for concentration versus time.
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Figure 2.26 Left ﬁgure: Age versus random eﬀect of clearance; Right ﬁg-
ure: Weight versus random eﬀect of clearance. There is some
positive association between weight and random eﬀect of clear-
ance.
∙ Gender histogram (bottom right): some male patients have highest peak in time plot.
Patients with high peak have been highlighted with orange, while those with low peak have
been marked with blue. From this ﬁgure, patients have high peak generally have low weight.
Curves with 100mg dose cluster at bottom. Also, patients with heavy weight may have lower
peak than patients with light weight.
Let’s look at model ﬁtted by NONMEM. Most outliers in a scatter plot of mixed eﬀect
(IPRE) versus concentration(CONC) comes from patients with 250mg dose.
Using interactive graphics, I am going through each evaluating criteria one by one: 1) max-
imum time to peak: this value directly aﬀects response of patients; 2) maximum concentration:
high response may give side eﬀects to patients; 3) AUC: the eﬀective period for drug. We can
see that all highest residual can contribute to patients with dose: 100mg, light weight, which
means something.
2.4.11 Summary of model ﬁt ﬁndings
Here is a summary of the main ﬁndings:
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Figure 2.27 Diagnostics plot. Patients with the largest response have low
weight.
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1. For all subjects, the concentration peaks quickly, around 0-2 hours, and then decreases
slowly.
2. Each subject responds diﬀerently: the peak concentration varies by subject, and the time
to peak diﬀers.
3. The mixed eﬀects model ﬁts better than the ﬁxed eﬀects model (Figure 2.23). This
suggests subject to subject variation is important and not well-modeled by the covariate
weight.
4. In this model, weight is found to have positive association with clearance (CL).
5. All of the models fail to capture the peak height for these 10 patients. Under estimating,
the maximum concentration could be problematic in providing side eﬀects from a drug.
To improve model, the mathematical model will need adjusting.
2.5 Conclusions
Because of the complexity of PopPK models, it is essential step to check model assumptions
and goodness of ﬁt during model building. Two case studies were utilized to demonstrate these
tests for exploration data analysis, goodness of ﬁt, parameter and random eﬀects evaluation,
structural model diagnostics, residual model diagnostics and covariate model diagnostics.
In addition, we applied interactive graphics to PopPK model diagnostics. With brushing
and linking, it helped to identify inﬂuential patients and evaluate model robustness. To our
knowledge, this is the ﬁrst attempt to implement interactive graphics in pharmacokinetic ﬁeld,
and this new approach will enrich the ﬁeld of model diagnostics and provide systematic view
of pharmacokinetic data.
47
CHAPTER 3. VISUALIZING RESAMPLING STATISTICS FOR
POPULATION PHARMACOKINETIC MODELING
Modiﬁed from a paper to be submitted to Journal of Biomedical Informatics
Xiaoyong Sun1,2, Dianne Cook1,2
1Binformatics and Computational Biology Program, 2Department of Statistics
Iowa State University, Ames, Iowa 50011, USA
Abstract
This work develops methods for diagnosing pharmacokinetic (PK) models by visualizing re-
sampling statistics, such as case deletion and bootstrap. Population pharmacokinetic (PopPK)
modeling targets the dose-concentration eﬀect of drugs. Its application has grown in this
decade because it can deal with a large number of patients, sparse sampling strategy, and an
unbalanced design. Resampling statistics assist in model validation because they provide a
way to measure the uncertainty of parameter estimates, and the inﬂuence of individuals. In
this work, we adapt visual methods from multivariate analysis, parallel coordinate plots and
multidimensional scaling, to examine resampling statistics. Multiple models are ﬁt, parameter
estimates and ﬁt diagnostics are extracted and the results are visualized. With careful scaling
the dependencies between diﬀerent statistics can be examined and single patient ﬁts better
understood. This work is implemented in the R package, PKgraph.
3.1 Introduction
Graphics has been proven to be an important tool to detect patterns, screen outliers, and
test hypotheses (Ette and Ludden, 1995; Ette, 1998; Ette et al., 2001a; Petricoul et al., 2001;
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Karlsson and Savic, 2007; Ene I. Ette, 2007). In the ﬁeld of pharmacokinetics, many multi-
dimensional data are generated to address various biological questions. Ette (1998) gives a
comprehensive tutorial on applying statistical graphics to pharmacokinetics and pharmacody-
namics. By explaining each plot type in detail, he systematically reviewed the application of
graphics and pointed out that “the use of graphic techniques in data visualization aids un-
derstanding of the data structure that would lead to an informative data analysis”. At the
same time, from a model perspective Karlsson et al. (1998) investigated assumption testing
comprehensively for population pharmacokinetic model (PopPK) based on graphics. In that
paper, the authors described 22 assumptions for various situations during the model devel-
opment. Bonate (2005) gave a detailed demonstration on how to facilitate modeling building
with graphics. With real PopPK examples, he went through each stage of model building
process with graphics. Recently, some new graphical approaches have been developed and ex-
plored. Bhasi et al. (2006) developed a novel multidimensional visualization technique called
VizStruct. Through a simulated data set, the author demonstrated a subtle diﬀerence between
one and two compartment models.
Resampling techniques have been widely applied to PopPK modeling to assess the uncer-
tainty of parameters, detect inﬂuential observations and test hypothesis (Bruno et al., 1996;
Ette, 1997; Langdon et al., 2005; Lehr et al., 2010). Generally, hundreds or thousands of resam-
pling statistics are generated for speciﬁc research goals and users tend to examine the numeric
rather than graphical summaries. The PopPK model ﬁtting employs complex algorithms, and
visualizing the resampling statistics can assist in obtaining a deeper understanding of the data
and model.
In this paper, we demonstrate how to visualize resampling statistics using multivariate data
plots and interactive graphics. Visualization techniques include parallel coordinate plots, and
low dimensional projections. Linking between plots using interactive graphics, helps to digest
the ﬁndings and explore associations between statistics. We believe this is the ﬁrst attempt
in pharmacokinetic ﬁeld to incorporate interactive graphics for resampling data analysis. This
paper is organized as follows. Section 2 explains the statistical graphics and methods. Section
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3 reports the results for this research. The discussion and conclusions are combined in Section
4.
3.2 Statistical graphics and methods
3.2.1 Overview of resampling statistics
Resampling statistics is a term used to describe statistical methods that take multiple
samples from a data set, and calculate quantities on each. These methods include bootstrap
which help measure uncertainty associated with parameter estimates (Shao and Tu, 1995; Efron
and Tibshirani, 1994; Davison and Hinkley, 1997), and case deletion methods, which help to
detect outliers that overly inﬂuence the model ﬁtting.
In the ﬁeld of pharmacokinetics, case deletion methods delete all of the observations for
a subject. The model is ﬁt for the reduced data set, and the subject is considered to be
inﬂuential if the parameter changes substantially. The process is repeated for each subject.
Some methods allow the deletion of groups of subjects, which would guard against the masking
of inﬂuence among subjects. In some circumstances single observations may be deleted and
the model ﬁt to ﬁnd single inﬂuential data points.
Bootstrapping is sampling with replacement (Efron, 1979). By taking many bootstrap
samples, and re-ﬁtting the mode, the distribution of the parameter estimates can be explored.
This method is typically used to add error bands or conﬁdence intervals around the parameter
estimates.
When multiple simulated data sets are created and models ﬁt the resampling statistics
data, the ﬁnal form is shown in Figure 3.1.
3.2.2 Statistical graphics
Starting simply, basic plots such as histograms and scatterplots, provide the fundamental
way to examine resampling statistics. In addition, we also examine the multivariate matrix
using specialized parallel coordinate plots and multidimensional scaling. We call these static
graphics. Linking between these representations allows us to better detect inﬂuential subjects.
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Patient ID (X):
1
2
Sim1      Sim2      Sim3      …      SimN (Y) CL
V
NA        0.53       0.65 0.52
0.61     NA          0.45                 0.62
0.47    0.45        NA
Ke
1
3
…
n
…          …            …                      …
0.35     0.34        0.21                 0.27
Figure 3.1 Multiple simulated data sets for resampling statistics. In the
ﬁrst simulation data set (sim1), when the subject is absent
from the simulation no parameter is estimated, so a missing
value (NA) is generated. One of these tables is generated for
each parameter (CL, V and Ke). We can consider this to be a
multivariate data set, which we will use to examine the inﬂu-
ence of each subject and assess the variability in the parameter
estimates.
The R packages lattice (Sarkar, 2008), and ggplot2 (Wickham, 2009) were used for producing
the static graphics, and rggobi (Temple Lang et al., 2009) for the interactive graphics.
3.2.2.1 Parallel coordinate plot
Parallel coordinate plot was developed by Inselberg (1985) and Wegman (1986). As the
name implies, a parallel coordinate system is used instead of an orthogonal axis system. This
enables the high-dimensional space to be represented on a two dimensional page. The con-
struction is as follows:
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1. A set of parallel axes is created usually from the columns of the data matrix. For our
usage each axes represents one simulation data set, matching each case deletion run in
this research.
2. To scale the values for comparison, global minimum and maximum were added to each
case deletion run. As a result, all values are scaled by diﬀerence between global min-
imum and maximum, which makes all simulation data sets comparable. For example,
in Figure 3.5 all case deletion runs have same unit length: 1.0 (global maximum) - 0.0
(global minimum) = 1, which puts all case deletion runs in same scale. These values for
each subject are marked in these axes.
3. The values for each subject are connected.
The ﬁnal results for each parameter are a set of plots that show how the parameter estimate
varies across simulations. If the estimate changes a lot we will see this, and it indicates that
the subject(s) deleted in that run was inﬂuential on the model ﬁtting.
3.2.3 Multidimensional scaling
Multidimensional scaling (MDS) transforms high dimensional data into low dimensional
representation of data while preserving the interpoint distances. It operates by minimizing a
loss function called “stress”, which measures the diﬀerence between the distances in the high
dimensional space and those in the low dimensional space. The low dimensional representation
is plotted. A good discussion of MDS can be found in Borg and Groenen (2009). There are
many possible loss functions for MDS, including classical, metric and non-metric scaling.
Bonate (2005) pointed out that principal component analysis would be a valuable tool
to identify inﬂuential cases. When the euclidean distance between points is used, which is
classical MDS, MDS performs like principal component analysis. More generally the MDS
framework allows a lot of ﬂexibility in how the low dimensional representation is constructed.
Using a diﬀerent distance metric and loss function can allow nonlinear mappings from high to
low dimensional space.
52
In this research we used classical MDS, to obtain a linear projection of the resampling
statistics data. The simulations were used as the dimensions, to be reduced. Thus, MDS is
summarizing the variability across the simulated data sets. Points correspond to the subjects.
3.2.4 Interactive graphics
Interactive or direct manipulation, graphics plots are active, so the user can make changes
in plots using mouse action. It is most useful if plots are also linked, so that changing the
elements in one plot propagates to all other visible plots. Some useful references include
McDonald (1982); Jog and Shneiderman (1995); Swayne and Buja (1998); Temple Lang and
Hornik (2001); Heer (2005); Unwin et al. (2006); Cook et al. (2007). In this paper, we linked
a histogram, scatter plot, parallel coordinate plot and MDS plot through interactive graphics.
3.2.5 Data
We illustrate visualizing resampling statistics using a data set from https://www.accp1.org.
The data contains 100 patients, and each individual was sampled with 0, 0.25, 0.5, 0.75, 1,
1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose. Several covariates were measured for each
subject, including weight (WT).
The resampling statistics were generated and ﬁtted using the cdd and bootstrap functions
in PsN (Lindbom et al., 2004), and the results were analyzed with R package, PKgraph. In
each bootstrap 100 patients were resampled and the number of bootstrap replicates was 50.
3.2.6 Model
Drug concentration was ﬁt by a one compartment model i.v. bolus model using NONMEM:
퐶푖푗 =
퐷표푠푒
푉푖
푒
−퐶퐿푖
푉푖
푡푖푗 (3.1)
All data were ﬁtted with NONMEM using the ﬁrst-order conditional method with interaction.
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3.3 Results
3.3.1 Resampling design
It is a good idea to double-check the design of the resampling. In the case deletion methods
each subject typically is sequentially deleted. For bootstrap we would expect the distribution
of subjects picked for the sample to be fairly uniform.
Figure 3.2 shows the resampling design plots. The plot on the left is for case deletion
diagnostics. In resampling data, each subject was not deleted sequentially for analysis. The
process is described by the PsN documentation as ﬁrst selecting subjects to form a “perturb”
pool. Subjects are basically deleted sequentially, and periodically the pattern is broken by
selecting one of the subjects from the “perturb” pool.
The plot on the right in Figure 3.2 is for bootstrap. A dot indicates that the subject was
selected for the sample. We would expect these to be fairly uniformly distributed over the
square, if the sampling is truly random. We have no reason to doubt that here because there
are no obvious patterns.
3.3.2 Distribution of demographic covariates in resampling data
Ideally the resampling design also is independent of the covariates used in the model ﬁtting.
To check this we plot the distribution of the covariates for each simulation. Figure 3.3 shows
density plots for the covariate, weight (WT), which is measured in kg. The density plot
generally reveals that subjects in the study were typically around 50kg, with another small
peak of overweight subjects around 95kg.
The left plot shows a density plot of weight (WT) for the case deletion statistics. Each
color indicates a diﬀerent simulation (sample with one subject removed). The distribution of
weight is similar for all samples. The right plot shows distribution of weight for each bootstrap
sample. We would expect to see more variation here than the case deletion statistics, and we
do. Some run only included light weight patients, resulting in a skewed distribution of weight.
54
Patient ID deletion plot for case deletion diagnostics
Case deletion run ID
D
el
et
ed
 ID
20
40
60
80
100
l
l
l
ll
ll
ll
ll
l
l
ll
ll
ll
ll
ll
l
ll
ll
ll
ll
ll
l
ll
ll
ll
ll
ll
l
ll
ll
ll
ll
ll
l
ll
ll
ll
ll
ll
l
ll
ll
ll
ll
ll
l
ll
ll
ll
ll
ll
l
ll
ll
ll
ll
ll
20 40 60 80 100
Bootstrap randomization check
Bootstrap ID
Su
bje
ct 
ID
20
40
60
80
100
l
l
l
l
l
l
l
ll
ll
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
ll
ll
l
l
ll
ll
ll
l
ll
l
ll
l
ll
l
ll
ll
l
ll
l
l
l
l
l
l
l
l
ll
ll
ll
l
l
ll
l
ll
ll
ll
ll
l
l
l
ll
ll
l
l
ll
l
ll
ll
l
l
ll
l
l
ll
ll
ll
ll
ll
ll
ll
ll
l
l
l
l
l
l
l
l
ll
l
l
ll
ll
ll
l
ll
ll
l
ll
ll
l
ll
l
l
ll
ll
ll
ll
l
ll
l
ll
ll
ll
l
ll
ll
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
ll
ll
l
ll
l
l
ll
l
l
l
l
l
l
ll
ll
ll
ll
l
l
ll
ll
ll
l
ll
l
ll
ll
l
l
l
ll
l
l
l
l
l
l
l
ll
ll
ll
ll
ll
l
ll
ll
l
ll
ll
ll
l
l
l
l
l
ll
ll
ll
ll
ll
ll
ll
ll
l
ll
l
ll
ll
ll
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
ll
ll
ll
l
ll
ll
l
ll
ll
l
l
l
ll
ll
ll
ll
ll
l
ll
ll
ll
l
l
ll
ll
l
l
l
l
l
l
l
l
ll
ll
l
ll
ll
ll
l
ll
l
l
ll
l
ll
ll
ll
l
l
ll
ll
ll
ll
l
l
ll
l
l
l
ll
ll
ll
ll
l
l
l
l
l
l
l
l
ll
ll
l
ll
ll
l
ll
l
ll
ll
l
ll
l
ll
l
ll
ll
l
ll
ll
ll
ll
l
ll
ll
l
l
l
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
ll
l
ll
ll
l
l
ll
l
ll
l
ll
ll
ll
l
ll
l
ll
ll
ll
ll
l
l
l
l
l
ll
ll
ll
l
l
l
l
l
l
l
l
l
ll
l
ll
ll
ll
l
ll
ll
ll
ll
l
l
ll
l
l
ll
l
ll
ll
l
l
ll
l
ll
ll
l
l
ll
ll
ll
l
ll
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
ll
l
ll
l
l
ll
ll
l
l
l
ll
ll
ll
ll
l
ll
ll
ll
l
l
l
l
l
ll
ll
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
ll
ll
ll
ll
ll
l
ll
ll
l
ll
l
l
ll
l
ll
ll
l
ll
ll
ll
ll
ll
ll
ll
ll
ll
ll
l
l
ll
ll
l
l
l
l
l
l
l
l
ll
ll
ll
l
ll
ll
ll
ll
ll
l
l
ll
l
l
ll
ll
l
l
ll
l
ll
ll
ll
l
l
l
l
ll
l
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
ll
ll
l
ll
l
ll
l
ll
l
l
l
ll
l
l
ll
l
ll
ll
ll
ll
ll
ll
ll
l
ll
ll
ll
l
l
l
l
l
l
l
l
ll
ll
l
ll
ll
l
l
ll
ll
l
l
l
ll
l
l
l
ll
l
ll
l
ll
l
ll
ll
l
ll
ll
ll
l
ll
ll
ll
ll
l
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
l
l
ll
ll
ll
ll
l
l
ll
ll
ll
ll
l
l
ll
ll
l
l
ll
ll
l
ll
ll
l
l
l
l
l
l
l
l
ll
l
l
ll
ll
l
l
ll
ll
ll
ll
l
l
ll
l
l
ll
ll
l
l
ll
l
l
ll
l
ll
l
l
ll
l
ll
ll
ll
l
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
ll
ll
ll
l
ll
l
l
ll
l
ll
ll
ll
ll
l
l
ll
ll
l
l
ll
ll
l
ll
ll
ll
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
ll
l
l
ll
l
ll
ll
l
ll
ll
ll
l
l
l
ll
ll
l
ll
ll
ll
l
l
ll
ll
ll
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
ll
ll
ll
l
l
l
l
ll
ll
l
ll
ll
l
ll
l
l
ll
l
l
ll
l
ll
l
l
l
ll
ll
ll
l
ll
l
ll
ll
l
l
l
l
l
l
l
ll
l
ll
l
l
ll
l
l
l
ll
ll
l
l
l
ll
l
l
ll
ll
l
ll
ll
l
l
l
l
l
ll
ll
l
l
ll
ll
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
ll
ll
ll
l
l
ll
l
ll
ll
l
l
ll
l
ll
ll
ll
ll
l
l
ll
ll
ll
ll
ll
l
ll
l
l
ll
l
l
ll
ll
ll
l
l
l
l
l
ll
ll
ll
l
ll
ll
l
ll
ll
l
ll
ll
l
l
ll
l
ll
l
l
ll
l
ll
ll
l
ll
ll
l
l
l
ll
ll
ll
ll
ll
ll
l
l
l
l
l
l
l
l
l
ll
ll
ll
l
ll
l
l
l
ll
ll
ll
ll
ll
ll
ll
l
ll
l
ll
l
l
ll
ll
ll
ll
l
l
l
ll
ll
l
ll
l
ll
ll
l
l
l
l
l
l
l
l
ll
ll
ll
l
l
ll
ll
l
l
l
l
l
ll
ll
l
ll
ll
ll
ll
ll
ll
l
ll
l
ll
ll
l
ll
l
l
l
ll
ll
l
l
ll
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
ll
ll
l
l
ll
l
ll
ll
ll
ll
ll
ll
ll
ll
l
ll
ll
l
l
ll
ll
ll
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
ll
l
ll
ll
ll
l
l
l
ll
l
ll
ll
l
l
l
ll
ll
ll
l
l
l
l
l
ll
ll
l
l
l
l
ll
ll
l
ll
ll
ll
l
l
l
l
l
l
l
l
l
ll
ll
ll
ll
l
l
ll
l
l
l
l
ll
ll
l
l
ll
ll
l
ll
ll
l
ll
ll
ll
ll
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
l
ll
ll
ll
ll
ll
l
l
ll
ll
ll
ll
l
l
l
ll
l
ll
ll
ll
l
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
ll
ll
ll
ll
l
ll
ll
l
ll
ll
ll
ll
ll
l
l
l
ll
l
l
ll
ll
ll
ll
ll
l
ll
ll
l
ll
ll
l
ll
l
l
l
l
l
l
l
ll
ll
l
ll
l
ll
l
l
ll
l
l
l
l
ll
ll
l
ll
l
ll
ll
ll
ll
ll
l
ll
ll
l
ll
ll
ll
ll
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
ll
ll
ll
ll
l
l
ll
l
ll
ll
l
ll
ll
ll
l
ll
l
ll
ll
l
l
ll
l
ll
ll
ll
ll
ll
l
ll
ll
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
ll
l
ll
ll
ll
ll
ll
ll
ll
ll
ll
ll
ll
l
ll
ll
l
l
ll
ll
ll
l
ll
l
l
l
ll
ll
l
ll
l
l
l
l
l
l
l
l
ll
ll
ll
l
l
ll
ll
l
l
ll
l
ll
l
ll
ll
ll
l
ll
ll
ll
ll
l
l
l
ll
l
l
l
ll
ll
l
l
l
ll
ll
ll
l
l
l
l
l
l
l
ll
ll
ll
ll
ll
ll
ll
ll
ll
l
ll
l
ll
ll
ll
l
l
l
ll
ll
ll
ll
ll
ll
ll
ll
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
ll
ll
ll
ll
l
ll
ll
l
l
l
l
ll
ll
l
l
ll
ll
ll
l
ll
ll
ll
ll
ll
ll
l
l
ll
ll
ll
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
ll
l
ll
ll
ll
ll
l
l
ll
l
ll
ll
l
l
ll
ll
ll
ll
l
l
ll
l
l
ll
l
ll
l
ll
ll
l
ll
l
ll
ll
l
l
l
l
l
l
l
l
ll
l
l
l
ll
ll
l
ll
ll
ll
ll
ll
l
ll
ll
ll
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
ll
l
ll
l
ll
l
l
l
l
l
l
l
l
l
ll
ll
ll
l
ll
l
ll
ll
ll
ll
ll
l
l
l
ll
ll
l
ll
l
ll
ll
ll
l
ll
ll
ll
l
l
ll
ll
ll
l
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
l
ll
ll
ll
ll
l
l
ll
l
ll
l
ll
ll
ll
ll
ll
ll
ll
l
l
ll
l
ll
l
l
ll
l
ll
l
ll
ll
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
l
l
l
ll
ll
l
ll
l
l
l
ll
l
ll
ll
ll
l
l
ll
l
ll
ll
l
ll
ll
l
l
l
l
ll
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
ll
ll
l
ll
ll
l
ll
ll
l
l
l
ll
l
l
ll
ll
ll
l
ll
ll
l
ll
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
ll
ll
ll
l
ll
l
ll
ll
ll
ll
l
ll
ll
l
l
ll
l
ll
ll
ll
ll
l
ll
ll
ll
ll
l
ll
l
l
ll
l
l
ll
l
l
l
l
l
l
l
ll
l
ll
ll
l
l
l
l
l
ll
l
ll
ll
ll
ll
l
l
ll
ll
l
l
l
ll
ll
ll
l
l
l
l
l
ll
ll
l
ll
ll
ll
ll
ll
l
l
l
l
l
ll
ll
ll
l
ll
l
ll
ll
l
l
l
ll
ll
ll
l
l
l
ll
ll
ll
ll
ll
ll
ll
ll
ll
ll
ll
l
l
l
l
ll
ll
l
ll
ll
l
l
l
l
l
l
l
ll
ll
ll
ll
ll
ll
ll
l
l
l
ll
l
l
ll
l
ll
l
ll
ll
ll
ll
l
ll
ll
ll
ll
ll
ll
ll
ll
l
l
l
l
l
l
ll
l
l
l
l
l
ll
ll
l
l
ll
ll
ll
ll
ll
ll
ll
l
l
l
ll
l
ll
l
ll
ll
l
ll
ll
l
ll
ll
ll
ll
l
ll
ll
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
ll
ll
ll
l
l
ll
ll
ll
l
ll
ll
ll
ll
l
l
l
l
l
l
ll
ll
ll
l
ll
ll
ll
ll
l
ll
ll
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
ll
ll
ll
ll
l
ll
l
l
ll
ll
ll
ll
l
l
ll
l
l
l
l
l
l
l
ll
ll
ll
l
ll
ll
ll
l
ll
l
ll
l
l
l
l
l
l
l
ll
ll
l
l
l
l
ll
l
ll
l
l
l
ll
ll
l
ll
l
ll
ll
ll
ll
ll
l
ll
l
l
l
l
ll
l
l
l
ll
ll
l
l
l
10 20 30 40 50
Figure 3.2 Plots to examine the resampling designs (left) for case deletion,
(right) bootstrap. In each case the run id is plotted horizontally,
and the vertical axis displays which cases were in or out of the
sample. For the case deletion design we plot the id number of
the subject deleted for the run. Lines connect sequential runs.
If the deletion was done sequentially by PsN then we would see
a straight line from (1,1) to (100, 100). This is not the case: in
the ﬁrst run, the ﬁrst patient was deleted, in the second run,
the 10th patient was deleted, and in the third run, the 100th
patient was deleted.
3.3.3 Distribution of parameter in resampling data
Estimates of the model parameters, such as clearance (CL), and volume of distribution
(V), determine the model ﬁt. Examining the density of these estimates across samples can be
useful also. Figure 3.4 shows the distribution of clearance for each sample. The basic shape
is bimodal, which means that there are two concentrations of clearance around 0.275, and 0.5.
The left plot shows the case deletion statistics. The distribution of clearance is fairly similar
for most samples. There is one subset where the clearance is much higher in the second mode.
The right plot shows the distribution of clearance in the bootstrap samples. There is a lot
more variability than the case deletion samples, but no individual sample that has substantially
diﬀerent density than the others.
55
Weight
de
ns
ity
0.005
0.010
0.015
0.020
0.025
40 60 80 100
Weight
de
ns
ity
0.005
0.010
0.015
0.020
0.025
0.030
40 60 80 100
Figure 3.3 Distribution of weight for the samples: (left) case deletion
statistics (right) bootstrap. Each sample is represented using a
diﬀerent color. The density is similar across the case deletion
samples. There is a lot more variation in the distribution of
weight in the bootstrap samples, as is to be expected.
3.3.4 Parallel coordinate plot and multidimensional scaling for case deletion di-
agnostics
Figure 3.5 shows the parallel coordinate plot for the scaled estimates for clearance for each
model ﬁt. Values for each simulation are connected, and diﬀerent colors are used. Values
for each subject are connected. There were two samples that caused the estimated clearance
values to change substantially when they were deleted (marked with red arrows). These are
subjects 52 and 20. Subject 52 has a very low clearance value generally, so it is one of the
extremes on the data, and its eﬀect on other subject’s clearance values is eﬀectively to push
them away from the mean, when it is included in the sample. This subject is an outlier, and
inﬂuential. Subject 20 has medium value of clearance, so it is not an outlier. When it is
deleted the estimated clearance for most other subjects drops, which means that the estimates
are inﬂated when it is included in the sample.
Figure 3.6 shows the MDS plot. Patient 52, 20 are outliers in this plot suggesting that they
are inﬂuential on the clearance estimates.
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Figure 3.4 Distribution of clearance (CL) in (left) case deletion statistics,
and (right) bootstrap samples. There is more variability in the
bootstrap samples, as expected. In the case deletion samples,
one run had a noticeably higher second peak than those in other
samples.
3.3.5 Interactive graphics
The parallel coordinate plot and MDS plot can be linked to check if the two observations
identiﬁed as inﬂuential are the same, and also linked to a plot of the subject concentration
proﬁles. This is shown in Figure 3.7 in the ggobi software. The two outlying observations in
the MDS plot (right) are brushed (red, blue). Linking is obtained using the ID of the sample
(resampleID). The points corresponding to these two samples are colored simultaneously in
the parallel coordinates plot (left). This was the approach that we used to learn that these are
the same two subjects identiﬁed earlier as inﬂuential. These two subjects are also highlighted
in the time series plots of the concentration for all subjects (middle).
After the two subjects: 52 and 20 were deleted, clearance (CL) changed clearly (middle)
from Figure 3.7 (left), we cannot tell the diﬀerence of these two subjects from others. The
linked plots allow us to compare the information learned separately from individual plots, and
examine the other information about these subjects.
Figure 3.8 shows how interactive graphics can be useful in examining the bootstrap statis-
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Figure 3.5 Parallel coordinate plot for diagnosing case deletion runs for
the clearance estimates. Each line in the ﬁgure connects values
for each subject, across runs. The clearance estimates change
substantially for two runs, suggesting there are two patients
which have undue inﬂuence on the model ﬁt.
tics. At left is a scatter plot of the variance in the clearance estimates plotted against ordered
ID. The subject having the largest variance in the clearance estimates is brushed (blue). This
plot is linked to the time series plots of concentration by subject (right). This subject (13)
had very low concentration.
3.4 Conclusion
This paper describes new visualization methods for resampling statistics including case
deletion and bootstrap. Two new multivariate graphics were designed. How to use interactive
graphics to explore for associations between ﬁndings and parameters was discussed. And simple
plots to examine the resampling design and distributions of parameter estimates and covariates
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Figure 3.6 MDS plot for diagnosing case deletion runs for the clearance
estimates. The IDs in the ﬁgure match the case deletion run
ID, and it means that the patient with this ID was deleted.
The plot indicates that subjects 52 and 20 were inﬂuential on
clearance estimates.
for the samples were also described. These methods are implemented and available in the R
package PKgraph. This research presents an important contribution to the ﬁeld of PopPK
modeling, and enhances the existing methods for diagnosing these models.
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Figure 3.7 Interactive graphics for case deletion diagnostics: (left) parallel
coordinate plot, (middle) time series plot for all patients, and
(right) MDS plot. Two outliers with case deletion ID: 52 and 20
are brushed in the MDS plot, and the corresponding elements
of the other two plots are colored accordingly. The two outliers
in the MDS plot correspond to the runs in the parallel coordi-
nates plot indicating the same two subjects as being inﬂuential.
The time series plots would not have suggested that these two
subjects are inﬂuential.
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Figure 3.8 Interactive graphics for bootstrap statistics. In the left side plot
variance of clearance estimates is plotted against subject ID.
There is one subject with very large variance, which is brushed
(blue). The plot is linked to the time series plot for all subjects
(right). This patient has very low concentration.
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Abstract
Population pharmacokinetic (PopPK) modeling has become increasing important in drug
development because it handles unbalanced design, sparse data and the study of individual
variation. However, the increased complexity of the model makes it more of a challenge to
diagnose the ﬁt. Graphics can play an important and unique role in PopPK model diagnostics.
The software described in this paper, PKgraph, provides a graphical user interface for PopPK
model diagnosis. It also provides an integrated and comprehensive platform for the analysis
of pharmacokinetic data including exploratory data analysis, goodness of model ﬁt, model
validation and model comparison. Results from a variety of modeling ﬁtting software, including
NONMEM, Monolix, SAS and R, can be used. PKgraph is programmed in R, and uses the R
packages lattice, ggplot2 for static graphics, and rggobi for interactive graphics.
4.1 Introduction
Population pharmacokinetic (PopPK) models in drug development study the absorption
and distribution of a chemical substance in a living organism. Compartmental analysis uses
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kinetic models to describe and predict the concentration-time curve, as the drug moves through
various compartments in the organism. It is generally preferable to noncompartmental analysis
in which only the total drug exposure is estimated. The population pharmacokinetic (PopPK)
model was developed (Sheiner et al., 1972, 1977) to adjust for individual characteristics in the
drug response. In the ﬁeld of Statistics the PopPK model is called a mixed eﬀects model,
using ﬁxed eﬀects to estimate demographics such as gender, and random eﬀects to quantify
the individual variation. It would also be considered a nonlinear model in that the absorption
and elimination of the drug is considered to follow speciﬁc kinetics. The PopPK model has
become the standard method used in drug development in the past decade, and has been
further developed by new algorithms and ﬁtting procedures (Samara and Granneman, 1997;
Sun et al., 1999; Ette et al., 2004).
NONMEM (Beal and Sheiner, 1980) was a software developed speciﬁcally for PopPK mod-
eling. General purpose software such as SAS NLMIXED, R nlme, WinBUGS and Monolix
can also be used to ﬁt the models. Although popular, NONMEM has limited functionality
for diagnosing the model ﬁt, providing simply the parameter estimates and some basic scatter
plots. In response, several software packages have been developed to enrich NONMEM, Xpose
(Jonsson and Karlsson, 1999), Census (Wilkins, 2005a), and PsN (Lindbom et al., 2004), etc.
Xpose is an R package that provides additional functionality for NONMEM, such as graphics
for exploring the data, covariate selection, model comparison and diagnosis. Census is a Win-
dows front-end that helps manage NONMEM and facilitate the use of Xpose. PsN includes
several computer intensive model validation techniques, using case-delete-one, bootstrap, and
jackknife subsampling.
The PKgraph software (Sun, 2010) reported in this paper provides a supplement to these
existing packages. It provides some additional advantages: (1) interactive graphics to link
plots of multiple features for data exploration and model diagnosis, (2) an integrated and
comprehensive platform for model diagnostics, and (3) access to model-ﬁtting a wider variety
of modeling software, Monolix, SAS NLMIX, R nlme in addition to NONMEM. PKgraph is
programmed in R, and uses the R packages lattice, ggplot2 for static graphics, and rggobi for
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interactive graphics.
The paper is organized as follows. Section 2 gives an overview of the software and explains
the speciﬁc functionality. Section 3 demonstrates how to use this software using an example
NONMEM data set. Future work is discussed in Section 4.
4.2 PKgraph infrastructure
PKgraph is a platform designed for PopPK model diagnostics. The main functions consist
of exploratory data analysis, PK model diagnostics, model validation (case deletion diagnostics
and bootstrap), and model comparison. The software incorporates a key concept: interactive
graphics to link various datasets and diagnostics plots. The framework is programmed using
RGtk2 (Lawrence and Temple Lang, 2009) and consists of two types interfaces (Figure 4.1),
(1) main, containing links to all parts of the software, and handles the basic data man-
agement, and links to diagnostic modules, and (2) graph, which provides tools speciﬁcally for
each diagnostic module.
4.3 Graphical user interface
4.3.1 Main interface
The main interface (Figure 4.2) of PKgraph provides the links to all components of the
software. There are four areas: (1) tool area (tool bar and menu bar, top), (2) directory area
(middle-left), (3) data area (middle-right) and (4) status bar (bottom). The tool area (1) has
menu items linking to the basic management modules (project, conﬁguration, data manage-
ment) and the diagnostic modules (exploratory data analysis, PK models, model validation,
model comparison and interactive diagnostics). These are menu items containing numerous
functions associated with each of the diﬀerent types of diagnostics. The directory area (2)
shows current directory and all of its ﬁles. These ﬁles might be data ﬁles, or code, depending
on the modeling software used. Clicking on any of the data ﬁles, will open them and display
them in the data area (3). Choosing the ﬁle also brings up a panel allowing for diﬀerent formats
to be read, thus handling all possible modeling software formats. The data ﬁles might contain
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ConfigurationOutput
Graphical User Interface
NONMEM, R nlme,
Monolix, SAS NLMIXED
Input
Exploratory Data 
Analysis
Model Validation Model 
Comparison
Interactive 
Graphics
Goodness of Fit
Additional R packages: lattice, 
ggplot2, rggobi
Figure 4.1 Software architecture of PKgraph. Blue indicates the manage-
ment interface and basic modules, and green the graphical in-
terface accessing the diagnostic modules. Data can be model
ﬁt results from NONMEM, Monolix, SAS or R, and users can
manage the data through graphical user interface to perform
model diagnostics. Figures can be generated and save based on
two R graphic packages: lattice and ggplot2.
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raw data, and model diagnostics such as parameter estimates, ﬁtted values and residuals and
these are displayed in the table view of the data area. The stats bar displays the progress of
the diﬀerent functions, for example here it says “Data is loaded successfully” to indicate that
there were no problems with opening the data ﬁle.
1
2 3
4
Figure 4.2 Main interface of PKgraph. Area 1 has menu items linking to
the basic management modules, and the diagnostic modules.
Area 2 shows current ﬁles. Area 3 is the data area, showing
model ﬁt from NONMEM. Area 4 displays the progress of load-
ing data.
4.3.2 Graph interface
The graph interface (Figure 4.3) provides speciﬁc functionality for diagnostic modules.
Selecting an item from one of the menus on the main interface brings up a graph interface.
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The style of the interface is the same for all of the diagnostic modules. It contains three areas:
1) parameter setup area, 2) tool bar, 3) plot area.
Figure 3 shows the interface that appears when a user selects the univariate plots item from
the exploratory data analysis menu. The parameter area setup (1) allows choice of variable,
plot labels, layout for trellis or facetted plots. A choice of lattice or ggplot2 graphics is provided.
The tool bar (2) allows the plots to be saved, opening the plot in ggobi for interaction on the
plot, synchronize subset selection from ggobi to the data in R, and close ggobi. The plot area
(3) displays the ﬁgure, and multiple ﬁgures if more than one are created.
4.4 Basic module
This functional unit is the main management platform of PKgraph. It consists of the
following operations: process input data, conﬁgure diagnostics, manage data, and output
either data or graphics for further usage.
4.4.1 Data Input/Output
PKgraph takes model ﬁt results from NONMEM, Monolix, SAS and R as input data. The
input ﬁle types should be a text ﬁle, either as txt or csv format. For example, in NONMEM,
using $TABLE the user can specify the interested variables and output ﬁle name to produce a
ﬁle for PKgraph.
Generally, PKgraph requires the following variables for post-processing: unique ID for each
patient, time, concentration (CONC), dose, model parameters such as clearance (CL) and vol-
ume of distribution (V) , model diagnostics such as residuals (RES), or weighted residuals
(WRES), and covariates such as weight, height and gender. By matching these variables to
a default metric system, the software can recognize the value of these variables and perform
routine operations, such as automatically generating plots for exploratory data analysis and
PopPK model diagnostics. For model validation such as bootstrap and case deletion diagnos-
tics, users can specify the directory and ﬁle name to process these hundreds or even thousands
of runs, and then visualize these results using PKgraph.
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Figure 4.3 Graph interface of PKgraph. It shows the histogram for con-
centration generated from lattice graphic package. Area 1 is
parameter setup area for ﬁgures. Area 2 shows tool bar (four
buttons) for the following four functions: saving, opening the
plot in ggobi for interaction on the plot, synchronizing subset
selection from ggobi to the data in R, and closing ggobi. Area
3 is the data area, showing model ﬁt from NONMEM. Area 4
displays the ﬁgure, and multiple ﬁgures if more than one are
created.
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4.4.2 Conﬁguration
The purpose of conﬁguration module is threefold: 1) set up the working directory for
current projects; 2) set up a format for saving ﬁgures; 3) set up additional annotations for
ﬁgures. Currently PKgraph supports bmp, jpeg, png, tiﬀ, pdf and win.metaﬁle formats for
saving ﬁgures. Multiple choices will generate multiple ﬁgures with all selected formats. Colors
can be set, and a choice of line types, such as a loess ﬁt, can be added to any ﬁgure. Users
need to set up basic choices in the conﬁguration before using the functional modules, and the
conﬁguration is saved for further analysis.
4.4.3 Data management
This module currently has two functions: subset and factor. The subset function enables the
user to select subgroups for further analysis. The factor function is utilized to setup categorical
variables if needed. Often variables have numerical values, such as 0=male and 1=female, which
may be interpreted as numerical data when it should be considered to be categorical. Correct
interpretation of variables as factors is important for much of the functionality in PKgraph.
4.5 Diagnostic modules
When the data is imported into PKgraph, and the conﬁguration is complete, users can
execute the following functions for model diagnostics: exploratory data analysis, goodness of
ﬁt, model validation and model comparison.
4.5.1 Exploratory data analysis (EDA)
EDA helps to ﬁnd patterns in the data, and explore for unexpected features, such as,
subjects with a drug concentration pattern that is diﬀerent from other subjects, individual
concentrations that are unusually extreme, whether males and females follow similar elimina-
tion trends, or if the patient’s weight changes the elimination pattern. Generally, histograms
and scatterplots are used for univariate and bivariate data. PKgraph provides univariate and
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bivariate data analysis panels for EDA. To explore multivariate data, PKgraph also oﬀers
scatterplot matrices and parallel coordinates plots (Inselberg, 1985).
4.5.2 PK models
The PK models module is designed to enable the user to assess the model ﬁt. There are a
lot of tools in this module, which include:
∙ Conﬁgure model results: PKgraph expects to see this set of variables, ID, TIME, CONC,
CL, V, PRED, IPRE, RES, and WRES, matching the naming system of NONMEM. If
the data has diﬀerent names for these variables, the conﬁgure panel allows the user to
match them to these quantities. Setting up these variables is important for eﬃcient
model ﬁt assessment.
∙ Individual plots: Make plots of each patient. Generally users make a scatterplot of
concentration versus time for each subject, while this module also provides functionality
for any scatterplots of any pair or variables for each subject.
∙ Check goodness of ﬁt
– Basic goodness of ﬁt: The selection of plots in this panel helps to assess the model
performance. They include scatterplots for concentration versus predicted values,
concentration versus predicted values for random eﬀects, predicted values for ﬁxed
eﬀects versus random eﬀects, and these values versus time.
– Parameters: Generally, the model ﬁtting procedure requires certain assumptions
about the distribution of parameters. These assumptions are checked using his-
tograms. In addition, the correlation between parameters can aﬀect model perfor-
mance, and this can be checked by scatterplots or a scatterplot matrix.
– Random eﬀects: As we did for parameters, we also need to check distribution and
correlation for random eﬀects using histogram, scatter plot or a scatterplot matrix.
∙ Check model assumptions
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– Structural model: In practice, there are three popular structural models, 1-, 2-
, 3-compartment models with diﬀerent absorption models. The structural model
can be diagnosed by plotting predicted values versus concentration conditioned on
time, predicted values for random eﬀects versus concentration conditioned on time,
weighted residuals versus time, weighted residuals versus predicted value, predicted
value versus concentration conditioned on covariates, predicted value for random
eﬀects versus concentration conditioned on covariates.
– Residual error model: Residual plots are a vital component of model assessment.
This panel allows the user to plot histograms and normal probability plots of the
residuals, and residuals versus predicted values, or residuals versus covariates. Two
assumptions (Karlsson et al., 1998) are related to this submodel: 1) homoscedastic
variability; 2) symmetrically distributed residuals. The plots above help to check
these two assumptions.
– Covariate model: Covariate models study how to incorporate covariates into the full
model. By linking subject-speciﬁc characteristics with model parameters, we can
identify the best covariates for model. The parameters estimates, random eﬀects and
weighted residuals are useful for screening covariates. We can utilize the following
methods to check covariate models: scatter plots for parameters versus covariates,
random eﬀects versus covariates, weighted residuals versus covariates, a scatterplot
matrix of covariates.
4.5.3 Model validation
Model validation makes use of several types of resampling methods. Bootstrap, where the
data is sampled with replacement, provides conﬁdence intervals for parameter estimates. Case
deletion methods leave a single value, or a single subject out, and re-ﬁt the model. These are
used to identify inﬂuential cases and subjects.
PKgraph oﬀers two approaches utilizing techniques. The ﬁrst is to examine the results
produced by PsN, which provides extensive resampling techniques for PK data. Alternatively
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users can do multiple model ﬁts, and compare these results in PKgraph. Users need to specify
a directory to read the PsN.
To visualize the results from resampling methods visual methods from multivariate anal-
ysis, parallel coordinate plots and multidimensional scaling (Figure 4.4), are used. Generally,
parallel coordinate plot was built as follows: 1) a set of parallel axes was created and these
axes matched exactly the data variables. Each axes represented one resampling, matching each
case deletion run in this research; 2) The values were marked in these axes scaled by respective
variables, representing the parameter values for all subjects in each case deletion run. To scale
the variables for comparison, global minimum and maximum were added to each case deletion
run; 3) The values from each patient across multiple case deletion runs were connected. In
this research, the parameter values (CL) for each subject were connected across axes. Multidi-
mensional scaling (MDS) can transform high dimensional data to low dimensional data by loss
function called “stress” and visualize the proximities (Borg and Groenen, 2009). There are
four kinds of MDS diﬀering in loss function (distance scaling versus classical scaling, metric
scaling versus nonmetric scaling. In this function, we used distance scaling to show diﬀerence
of multiple case deletion runs based on parameter values (CL).
4.5.4 Model comparison
This module allows users to compare two models. Users need to ﬁrst match the parameter
estimates for the two models, which is basically matching the column names or variable names
from two sets of results. There are then three choices for comparison: “histogram comparison”
(distribution comparison), “scatter plot comparison” and “transform comparison”.
The “histogram comparison” plots a histogram of each model’s results in order for the
distributions to be compared (Figure 4.13). The “scatter plot comparison” plots the values
from one model against those of the other model. The “transform comparison” transforms data
by ratio or log ratio in order to visualize the diﬀerence between variables from two models.
These model summary data sets can be passed into ggobi for interactive exploration.
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Figure 4.4 Graph interface for case deletion diagnostics. The left area is
the parameter setup area. The right area is the ﬁgure area.
In this ﬁgure, a multidimensional scaling plot is generated for
visualizing case deletion runs. The IDs in the ﬁgure match the
case deletion run ID, and it means that the patient with this
ID was deleted, and model was re-ﬁt with NONMEM.
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Figure 4.5 Model comparison. Top ﬁgure: “histogram comparison” for
comparing distributions of “CL” from two models. The left area
is parameter setup area. In the setup, clearance (CL.x, CL.y)
from two models are compared. The ﬁgure shows that there
is not much diﬀerence between two models in the distribution
of CL. Bottom ﬁgure: “scatter plot comparison” for comparing
values of “CL” from two models. The ﬁgure shows that two
models are quite similar for small “CL” values, while there is
some diﬀerence for high “CL” values.
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4.5.5 Interactive graphics
This functional module incorporates a unique feature: interactive graphics into every step of
model diagnostics. It includes three steps: select datasets; conﬁgure mapping; and diagnostics,
and the resulting data set is passed into ggobi. By linking diverse data sets with a key variable,
users can seek patterns by brushing, linking and diagnosing patterns conveniently.
4.6 Example
A dataset from NONMEM is used to demonstrate the PKgraph software. It has 100
patients with the covariates, gender (ISM), age (AGE), and weight (WT). A one compartment
model with zero order absorption and ﬁrst order elimination is ﬁtted using NONMEM. The
text ﬁle containing the ﬁtted model results is imported into PKgraph. In the “open” dialog,
the ﬁle format for reading uses default parameters. If the data loads successfully it shows up
in the data panel at right, and a message, “Data is loaded successfully” appears in the status
bar at bottom of the GUI.
To explore data, we choose “Bivariates” from “Exploratory Data Analysis” located at menu
bar to check the scatter plots of interested variables. Figure 4.6 shows the concentration vs
time plots, where individual proﬁles are shown. We can see that concentration peaks at 0
consistent with the zero absorption model) and drops oﬀ rapidly for most patients. Studying
this relationship conditional on a covariate can be achieved by setting the variable in the “cond”
text box. Figure 4.7 shows the individual proﬁles separately for females (0) and males (1). We
can see that the concentration peaks are lower for females. The lattice package was used to
make these plots but users can choose to have them produced using the ggplot2 package.
Interactive graphics can be used to drill down into the data. Click the second image button
on the right panel. This will start ggobi and load the data. Two windows will be visible
console window and plot window (Figure 4.8). To open mode plots use the Display menu,
and select the type of plot, then select the variables to include. Here we have a proﬁle plot
of all of the individuals, and a scatterplot of weight versus age. In order to link the plots
appropriately users need to choose the “Brush” option on the ‘Interaction” menu, and select
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Figure 4.6 Exploratory data analysis. The left ﬁgure is the parameter
setup area. x, y are set as TIME, CONC; time variable is set as
TIME; ID variable is set as ID. The right ﬁgure is ﬁgure area,
showing concentration versus time (hr).
76
Figure 4.7 Exploratory data analysis. The left ﬁgure is the parameter
setup area. x, y are set as TIME, CONC; time variable is set as
TIME; ID variable is set as ID. The right ﬁgure is ﬁgure area,
showing concentration versus time (hr) conditioned on ISM (0:
female, 1: male).
77
ID as the variable to connect points in one plot with points in the other plot. In the proﬁle
plot subjects with the highest peak concentration are highlighted (blue) and the corresponding
covariate values for these subjects are highlighted in the other plot. These two subjects tend
to be slightly older and are light in weight.
Figure 4.8 The model results are loaded into ggobi for interactive explo-
ration. The plot at left shows the concentration versus time
for all subjects, and the plot at right shows two of the covari-
ates, weight versus age. The two plots are linked by subject
ID. Points near the peak concentration are brushed (blue) and
from the covariate plot we can see that these two subjects are
both light and relatively old.
The detailed information for these two patients can be examined by clicking the third
button in the toolbar of the PKgraph graph interface (Figure 4.9).
The next step is to check the model assumptions and diagnose the ﬁtted model, using the
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Figure 4.9 Exploratory data analysis. After clicking the third button in
toolbar (above ﬁgure area), the detailed information for two
patients (ID: 55 and 58) is selected for investigation.
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“PK model” option. Figure 4.10 shows a plot used to check the structural model, weighted
residuals versus predicted values. The residuals are relatively evenly spread between -3 and 3,
which says that the structural model looks ok.
Figure 4.10 Structural model diagnostics. The left area is parameter setup
area. It has default parameter setup, and users can change
them to their speciﬁc interests. The right area is ﬁgure area.
In this ﬁgure, it shows weighted residual (WRES) versus pre-
dicted values (PRED). The residuals are randomly distributed.
To dig deeper into the diagnostics, we can examine the resampling statistics generated by
PsN, using the “model validation” option. In this process, we have 100 NONMEM leave-one-
out runs saved in a directory generated by using PsN function, cdd. For these runs we examine
the clearance values (CL). The parallel coordinates plot is shown in Figure 4.11. Lines connect
the clearance values for each subject from the 100 models ﬁt with one subject excluded. We
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can see some patients have more inﬂuence on clearance than others, indicated by a big change
in the clearance for all subjects when this one is excluded.
Let’s identify these inﬂuential cases with interactive graphics. The data is loaded into ggobi
(Figure 4.12) and the parallel coordinates plot is linked to an MDS view of the multiple runs.
Brushing an outlier in the MDS plot shows that this subject (52) is one of the inﬂuential cases
in clearance values. We would also ﬁnd that subject 20 is the other inﬂuential case.
To compare model we use the “model comparison” option. Figure 4.13 shows the compar-
ison of an additive error model (2 CS1 IV1ESTFPDF.ﬁt) with proportional error model (3
CS1 IV1ESTFPDF.ﬁt2). The distribution clearance in two models, separately by gender, is
examined using a density plot. There is not a lot of diﬀerence, but the ﬁrst model has slightly
higher density values in the second clearance mode for both males and females.
4.7 Conclusion and future work
PKgraph is an R package for diagnosing population pharmacokinetic model ﬁtting. In
the framework supported by R graphics packages, lattice, ggplot2, and rggobi this program
can generate high-quality ﬁgures for FDA submission, and provide rapid diagnosis of models
using interactive graphics. This R package provides a user-friendly graphical user interface
so that the learning curve for users is reasonably short. The PKgraph software serves as
a supplement to the existing packages: NONMEM, Xpose and PsN for diagnosing models.
Currently PKgraph is based on rggobi for interactive graphics, and rggobi is not so ﬂexible to
be integrated with the whole system. The next step would be to incorporate a new R package:
qtpaint (qtinterfaces project group, 2009) to replace rggobi and provide a more ﬂexible and
faster working environment.
4.8 System requirements, availability and installation
PKgraph is an R packaged built on the following R packages: RGtk2, gWidgets, gWid-
getsRGtk2, lattice, and ggplot2. It requires R (>2.0) (R Development Core Team, 2008) and
GTK+, and runs under Windows, Linux and Mac. The detailed installation guide is available
81
Figure 4.11 Inﬂuence analysis for case deletion diagnostics. The left area
is parameter setup area. The right area is ﬁgure area. In
this ﬁgure, it is parallel coordinate plot for case deletion diag-
nostics. The y axis is case deletion run. Since there are 100
patients, there are 100 case deletion runs. Each run means
one patient ID is deleted, model is re-ﬁt, and parameter (CL
here) for this patient is calculated. X axis is the parameter
(CL) value. Each line in the ﬁgure matches parameters (CL)
for one patient across multiple case deletion runs. When two
patients were deleted in two case deletion runs (marked with
red arrows), the values of parameter CL of all other patients
changed clearly compared with those in other runs. Parameter
(CL) value for some patients increases, while other decreases.
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Figure 4.12 Inﬂuence analysis for case deletion diagnostics: linking re-
sults from multidimensional scaling and parallel coordinate
plots. The plot at left shows the parallel coordinate plot
(x=simulation ID, y=clearance), and the plot at right shows
multidimensional scaling plot. The two plots are linked by
case deletion ID. One outlier point (case deletion ID: 52) is
brushed (blue). When this subject is left out, the estimated
clearance values for other subjects are lower.
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Figure 4.13 Density plot comparison for comparing distributions of clear-
ance (CL) from two models (blue, pink), separately by gen-
der (ISM: 0=female, 1=male). The distribution of CL for
two models is slightly diﬀerent, for both genders: model 2
has slightly higher density of values at high clearance, with a
higher peak in the second mode.
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in the vignette with the package, and users are free to download PKgraph under the terms of
GNU license at http://cran.r-project.org/web/packages/PKgraph/index.html.
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CHAPTER 5. PKREPORT: REPORT GENERATION FOR CHECKING
POPULATION PHARMACOKINETIC MODEL ASSUMPTIONS
To be submitted to Computer Methods and Programs in Biomedicine
Xiaoyong Sun1,2, Dianne Cook1,2
1Bioinformatics and Computational Biology Program, 2Department of Statistics
Iowa State University, Ames, Iowa 50011, USA
Abstract
Graphics play an important and unique role in population pharmacokinetic (PopPK) model
building by exploring hidden structure among data before modeling, detecting extremity during
modeling, and validating results after modeling. We have seen that some practicing analysts
have their own code to generate a collection of their favorite diagnostic plots and statistics.
The work described in this paper is about a new R package called PKreport, which will
generate a collection of plots and statistics for testing model assumptions, visualizing data
and diagnosing models. PKreport provides 1) automate plots for users to visualize data and
models, 2) automatically generated R scripts that are used to create the plots; 3) implement an
archive-oriented management tool for users to store, retrieve and modify ﬁgures, 4) generate
high-quality graphs based on the R packages, lattice and ggplot2. The general architecture,
running environment and statistical methods can be readily extended.
5.1 Introduction
The application of population pharmacokinetic (PopPK) modeling in the drug development
has grown in this decade because it can handle unbalanced design and sparse data (Samara and
86
Granneman, 1997; Sun et al., 1999; Ette et al., 2004). However, this advantage does not come
without a cost. The complexity of statistical model brings diverse variability to the results, and
as a result, bias is a big challenge in some situation. Graphics play an important and unique
role in PopPK model building by exploring hidden structure among data before modeling,
detecting extremity during modeling, and validating results after modeling (Cleveland, 1993;
Karlsson et al., 1995; Ette and Ludden, 1995; Karlsson et al., 1998; Ette, 1998; Ette et al.,
2001b; Petricoul et al., 2001; Brendel et al., 2006; Karlsson and Savic, 2007; Ene I. Ette, 2007).
From the statistical perspective, Ette (1998) gave a comprehensive tutorial for graphics
application in PopPK modeling. By exploring distribution plots, scatter plots, residual plots,
partial residual plots, pairs plots, conditional plot, contour plots and start plots, he exten-
sively demonstrated the graphic ability in the ﬁeld of PopPK. At the same time, from a model
perspective Karlsson et al. (1998) investigated assumption testing comprehensively for PopPK
model based on graphics. In that paper, the authors described 22 assumptions for various
situations during the model development. By going through each stage of model building pro-
cess with graphics, Bonate (2005) gave a detailed demonstration on how to facilitate modeling
building with graphics, especially with the real PopPK examples.
In 1999, as a continuation of the work in 1998, Jonsson and Karlsson (1999) developed a
software tool: Xpose to help model building with graphics. Equipped with data set checkout
plots, goodness of ﬁt plots and tools for covariate model selection, this software has gained great
popularity. Later, Wilkins (2005a) further created a graphical user interface and management
tool: Census, to help Xpose diagnose models. In 2003, Monolix was developed based on SAEM
algorithms (The Monolix group, 2010). Monolix provides user-friendly graphical interface,
powerful and convenient PK/PD model library, goodness of ﬁt plots, and a standard-alone
non-matlab program.
However, these tools do not provide automatically generated routine graphics. For ex-
ample, the Federal Drug Administration (FDA) requires detailed graphical explanation, and
every submission requires tedious work to generate a large quantity of graphs. Census and
Monolix can only be utilized to diagnose models and generate ﬁgures for speciﬁc goals and
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there is no way to reduce time and cost for this routine work, especially that many data share
similar diagnostics. Secondly, it requires users to have expertise in statistical knowledge and
computational skills to generate all related graphs. This may provide obstacles to users who
do not have graphical expertise.
In this work, I developed an automatic report generator, PKreport, for testing model
assumptions, visualizing data and diagnosing models. PKreport provides 1) automate plots
for users to visualize data and models, 2) automatically generated R scripts that are used to
create the plots, 3) an archive-oriented management tool for users to store, retrieve and modify
ﬁgures, 4) high-quality graphs based on the R packages, lattice (Sarkar, 2008) and ggplot2
(Wickham, 2009). The general architecture, running environment and statistical methods can
be readily extended.
The paper is organized as follows. Section 2 explains the methods implemented in the
report. Section 3 focuses on the software implementation. Section 4 demonstrates how to use
this package. The conclusions and future work are discussed in Section 5.
5.2 Methods
Many authors (Ette, 1998; Karlsson et al., 1998) had done extensively research in model
assumption testing, and we followed these guidelines to automatically perform the following
assumption testing: 1) exploratory data analysis; 2) goodness of ﬁt plots; 3) parameter and
random eﬀects evaluation; 4) structural model diagnostics; 5) residual model diagnostics; 6)
covariate model diagnostics.
5.2.1 Exploratory data analysis
Dose history, covariate information, and diverse clinical trials for same purpose should
be checked for correctness and accuracy before analyzing models. Data structure should be
investigated to screen hidden patterns, outliers and extreme observations linked to individuals
for further analysis. Currently, histogram and scatter plot combined with conditional plot
were implemented to help achieve these goals. Karlsson et al. (1998) emphasized the plots for
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each patient ID versus each variable in the data ﬁle, and Ette (1998) described exploratory
examination of concentration, distribution and correlations between covariates. All of these
guidelines had been implemented in the PKreport package.
5.2.2 Goodness of ﬁt plot
Goodness of ﬁt plot plays a key role in checking model ﬁtting. These kinds of plots give
an overall perspective of model performance, including scatter plots for concentration versus
PRED, concentration versus IPRED, PRED versus time and IPRED versus time (European
Medicines Agency, 2007). Most reports submitted to FDA are required to explain response
from each patient. Individual plots for concentration/PRED/ IPRED versus time can be
explored for this purpose.
5.2.3 Evaluate parameters and random eﬀects
Generally, there are assumptions for distribution of parameters during modeling process.
The histogram was utilized to check this distribution. In addition, the correlation of param-
eters has signiﬁcant eﬀect on modeling performance, and it was checked by scatter plots or a
scatterplot matrix. The assumptions for random eﬀects were also tested for distribution and
correlation by histogram, scatter plots or a scatterplot matrix.
5.2.4 Diagnose structural models
Structural model describes the model without the covariates. In practice, there are three
popular structural models for use, including 1-, 2-, and 3-compartment models with diﬀerent
absorption models. After determining structural models, we can further build covariate models
by incorporating right covariates. Structural model was diagnosed by PRED versus concen-
tration conditioned on time, IPRED versus concentration conditioned on time, WRES versus
time, WRES versus PRED, PRED versus concentration conditioned on covariates, IPRED
versus concentration conditioned on covariates.
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5.2.5 Diagnose residual error models
Residual model deals with random and unexplained variability (휖 in the following function)
due to model misspeciﬁcation, assay errors, dosing history errors, etc.
푦푖푗 = 푓(푑표푠푒; 푡푖푗 ;훽푡) + 휖 (5.1)
Generally, PopPK model consists of the following common residual models (Karlsson et al.,
1995; Bonate, 2005):
∙ additive error model
푦푖푗 = 푓(푑표푠푒; 푡푖푗 ;훽푡) + 휖 (5.2)
∙ proportional error model
푦푖푗 = 푓(푑표푠푒; 푡푖푗 ;훽푡)(1 + 휖) (5.3)
∙ exponential error model
푦푖푗 = 푓(푑표푠푒; 푡푖푗 ;훽푡)푒
휖 (5.4)
∙ combined additive and proportional error model
푦푖푗 = 푓(푑표푠푒; 푡푖푗 ;훽푡)(1 + 휖1) + 휖2 (5.5)
Two assumptions are related to this submodel: 1) homoscedastic variability; 2) symmet-
rically distributed residuals. To test these assumptions, we applied the following techniques:
1) histogram for distributions of WRES; 2) histogram for individual distribution of WRES; 3)
scatterplot of ∣WRES∣ versus PRED to check the shape of residual; 4) scatterplot of ∣WRES∣
versus PRED conditioned on covariates to screen the covariate eﬀects; 5) autocorrelation of
WRES.
5.2.6 Diagnose covariate models
In general, covariate models study how to incorporate covariates into the model. By linking
subject-speciﬁc characteristics with model parameters, we can identify right covariates for
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model. Parameters, ETA and WRES are of great use to help screen proper covariates. We
utilized the following methods to check covariate models: 1) scatter plot for parameters versus
covariates, ETAs versus covariates, WRES versus covariates; 2) scatterplot matrix of covariates.
5.3 Software implementation
PKreport is an R package aiming to create an automatic pipeline for model assumption
testing. Based on a hidden metric system matching default variables to data variables, this
package turns the assumption testing to a fast, convenient and comprehensive routine. With
the support of two powerful R graphical packages (lattice and ggplot2 ), this software can
generate high-quality ﬁgures for diagnosis, archive all ﬁgures with speciﬁc folders for report
and review, and utilize web browsers as the interface for viewing, archiving and analyzing.
5.3.1 Metric system
The default variables function as the currency for communicating between data sets and
the package to generate special-purpose plots (Table 5.1). For example, PRED represents
prediction calculated from nonlinear mixed eﬀects model ﬁtting, and RES is equal to the
diﬀerence between observations and predictions (Boeckmann et al., 1994; Brendel et al., 2006).
Users may use preferred software to calculate these related variables. As a result, each data
set and ﬁtting results have totally diﬀerent variable names for further analysis. To facilitate
model diagnostics, users need to match the package metric system with the variables from
data sets. After matching, the package can process data, conﬁgure functions, and generate
related diagnostic plots. This system provides ways to function for diverse software such as
NONMEM, Monolix, R nlme package, and SAS NLMIX procedure.
5.3.2 Conﬁguration
The whole system is conﬁgured by three lists: 1) graph list. This list helps user to choose
proper ﬁgure format (jpg, pdf, png, etc.) as well as the graphical packages. Currently there are
two graphical packages implemented for high-quality ﬁgures (lattice and ggplot2 ). 2) histogram
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Package variable Description
ID Patient ID
TIME Time after dose
CONC The concentration of drug in the body
PRED Prediction generated from model ﬁtting
RES Residual
WRES Weighted residual
IPRED Individual prediction
IWRES Individual weighted residual
COV Covariates
Table 5.1 Package metric system. The ﬁrst column (Package variable)
contains default variable names. These default variable names
match NONMEM naming system. The second column explains
the details of these variables.
list. This list speciﬁes the conﬁguration for the histogram generated by this package. It includes
type of histogram and layout setup. 3) scatterplot list. This list determines type of scatter
plot, bandwidth of smooth and layout setup.
5.3.3 Architecture description and features
Currently PKreport oﬀers console user interface to test model assumptions. It has the
following functions: 1) Match metrics. By matching default package variables to data variables
based on one-to one or one-to-many schema, this function sets up global variables for further
analysis. 2). Conﬁgure ﬁgures. This module determines the ﬁgure format, ﬁgure size and
other related properties of ﬁgures. 3). Generate ﬁgures. Depending on the research goals,
users have access to 7 sub-functions for exploratory data analysis, overall goodness of ﬁt plots,
parameter diagnostics, random eﬀect diagnostics, structural model diagnostics, residual model
diagnostics, and covariate model diagnostics. Each sub-function will create a folder to store
related ﬁgures as archives. 4). Display results. PKreport oﬀers web browser as a management
tool to explore the archives created in function 3 and R scripts in function 5. The main interface
includes the names of ﬁle directories. 5). Generate R scripts. To improve eﬃciency and help
users to generate high-quality ﬁgures, users have option to modify related R scripts to meet
their speciﬁc requirements. All generated R scripts match the order of ﬁgures generated in
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function 4. 6). Modify ﬁgures. Users can also update or modify certain ﬁgures with ﬁgure ID
for particular purpose. 7). Clean archives. This module will delete all archives (ﬁle directories
and ﬁgures) and clean the global variables in R environment. The general architecture is shown
in Fig 5.1.
Global Variables
Match 
metrics
Configure 
figures
Generate 
figures
Generate 
R scripts
Display 
results
Modify 
figures
Clean 
archives
Archives
Figure 5.1 Software architecture of PKreport. It has seven main functions:
1) match metrics; 2) conﬁgure ﬁgures; 3) generate ﬁgures; 4)
display results; 5) generate R scripts; 6) modify ﬁgure; 7) clean
archives. The ﬁrst two functions set up working environment,
and the other functions help to generate related ﬁgures.
5.4 Demonstration
One data set from NONMEM was ﬁtted with one-compartment model and utilized for
demonstration of PKreport. The following R scripts enable users to input data, conﬁgure
package, generate ﬁgure, display ﬁgure from archives, and ﬁnally clean up the archives.
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Step 1: Read data and set up ﬁgure format.
> library(PKreport)
> data(pdata)
# setup configuration
> general.list <- list(save.format="bmp", width = 480, height = 480, package=2)
> hist.list <- list(type=c("count"), layout=c(1,1), ind.layout=c(5,5))
> scatter.list <- list(span=0.25, type=c("p", "smooth"), layout=c(1,1),
ind.layout=c(5,5))
Step 2: Match metric system.
> var.name <- list(ID="ID", DV="CONC", TIME="TIME", PRED="PRED", RES="RES",
WRES="WRES",IPRE="IPRE", IDV=c("CLCR", "WT"), COV=c("WT", "AGE"),
ETA=c("ETA1", "ETA2"), PARA=c("CL", "V"))
> PKdata(data=pdata, match.term=var.name)
> PKconfig(general.list, hist.list, scatter.list)
Step 3: Generate ﬁgures. Because of the page limit, I only demonstrate exploratory data anal-
ysis (PKreport.1), goodness of ﬁt plots (PKreport.2) and covariate model diagnostics (PKre-
port.6).
> PKreport.1(pdata)
> PKreport.2(pdata)
> PKreport.6(pdata)
Step 4: Display results in the web browser. Results are shown in Figure 5.2; Archives for
ﬁgures shown in Figure 5.3; Figures for speciﬁc diagnostics shown in Figure 5.4 (left ﬁgure
from R package: lattice, and right ﬁgure from R package: ggplot2 ); All related R scripts shown
in Figure 5.5.
> PKshow()
Step 5: Delete archives.
> PKclean()
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Figure 5.2 Diagnostic results shown in web browser. In this example,
the categories in web browser match three diagnostic steps:
exploratory data analysis (PKreport.1), goodness of ﬁt plots
(PKreport.2) and covariate model diagnostics (PKreport.6).
The last one contains all related R scripts.
5.5 Future
The next step for this work is for the package to be released to CRAN and tested by PopPK
modelers. We expect that several iterations of reﬁnements to the software for it to become
useful and commonly used by PopPK modelers.
5.6 Availability
PKreport is free to download at http://pkreport.sourceforge.net/.
95
Figure 5.3 Figure archives. In this example, univar and bivar folders
match exploratory data analysis; gof folder matches goodness of
ﬁt plots; cov folder matches covariate model diagnostics. These
folders contain all related diagnostic ﬁgures. PKcode.text has
all related R scripts for these ﬁgures.
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Figure 5.4 Figures for covariate model diagnostics. Left ﬁgure: scatterplot
of individual prediction (IPRE) versus concentration (CONC)
generated with lattice package. Right ﬁgure: scatterplot of in-
dividual prediction (IPRE) versus concentration (CONC) gen-
erated with ggplot2 package.
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Figure 5.5 R scripts generated for goodness of ﬁt plots. The ﬁgures gener-
ated with these R scripts are stored in gof folder. In this exam-
ple, the R scripts are for two scatterplots (IPRE versus CONC
and DOSE versus IPRE) and for each plot, the R scripts for
both lattice and ggplot2 packages are generated.
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Abstract
Covariate selection is one of most important components in population pharmacokinetic
(PopPK) model building. This paper examines the eﬀects of collinearity between covariates
on covariate selection and compares the performance of two new algorithms, gradient boosting
and random forests, with the existing generalized additive model (GAM) approach. We use
empirical Bayes estimates of each subject’s pharmacokinetic parameters covariates based on the
structural model to feed into the covariate selection procedures. Data was simulated using one
and two signiﬁcant covariates out of four, a single one compartment intravenous bolus model
was ﬁtted using NONMEM. We found that GAM is generally more sensitive to correlation
structure than the other two algorithms in the covariate selection.
6.1 Introduction
In any kind of model building the objective is to obtain a parsimonious model, one with
as few variables as possible that gives similar accuracy in prediction. Covariate selection is
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a major endeavor in population pharmacokinetic (PopPK) model building (Xiao and Fiedler-
Kelly, 2002; Miller, 1984; Maritre et al., 1991; Mandema et al., 1992; Jonsson and Karlsson,
1998; Wahlby et al., 2001; Wu and Wu, 2002; Bonate, 2005; Kowalski and Hutmacher, 2001;
Wahlby et al., 2002; Bies et al., 2006; Ribbing et al., 2007). Wu and Wu (2002) established
that an empirical bayes estimates (EBE) based method works the best. In this approach a
model without any covariates is ﬁt to the data, called the base or structural model. Each
subject’s pharmacokinetic parameters are then determined using Bayesian estimation. From
these estimates the covariates are screened using some regression-based approach. This is the
approach used in NONMEM.
In 1992, Mandema et al. (1992) applied a generalized additive model (GAM) as the covariate
selection method, using on empirical Bayes estimates for each subject. They showed that this
method runs much faster than stepwise approach taken by NONMEM. Wahlby et al. (2002)
investigated the selection bias related to stepwise selection procedures and found results favored
the GAM approach too. Jonsson and Karlsson (1999) implemented this method in Xpose based
on R package, GAM. Xpose has since become very popular.
Other methods examined recently include Wald’s approximation method (WAM) algo-
rithm to approximate a likelihood ratio test (LRT) (Kowalski and Hutmacher, 2001), genetic
algorithms (Bies et al., 2006) and lasso methods (Ribbing et al., 2007).
In this paper we report simulations used to address two questions:
1. How does the covariate correlation aﬀect the EBE-based covariate model building?
2. Will two alternative methods, gradient boosting and random forests, perform better than
GAM?
The paper is organized as follows. Section 2 explains the simulation setup and methods. Section
3 reports the results from GAM, gradient boosting and random forest. The conclusions and
future work are discussed in Section 4.
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6.2 Methods
6.2.1 Covariate data generation
The approach used by Mandema et al. (1992) is followed. Data was simulated using the
R package mvtnorm. Four covariates were used: weight-WT (median=85kg, range = 51-137),
height-HT (median=173 cm, range=140-188); age-AGE (median=56 years, range=25-69) and
alkaline phosphatase - AP (median=324, 32-615).
6.2.2 Correlation structure
To investigate the eﬀects of collinearity between covariates on the covariate selection, we
simulated data using the following four correlation matrices (Table 6.1- 6.4),
WT HT AGE AP
WT 1 A 0 0
HT A 1 0 0
AGE 0 0 1 0
AP 0 0 0 1
Table 6.1 Correlation structure 1: one true covariate (WT). A increased
by 0.1 from 0 to 1, resulting in 10 values.
WT HT AGE AP
WT 1 A B 0
HT A 1 0 0
AGE B 0 1 0
AP 0 0 0 1
Table 6.2 Correlation structure 2: one true covariate (WT). A increased by
0.1 from 0 to 1 and B decreased by 0.1 from 1 to 0 concurrently,
resulting in 10 combinations.
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WT HT AGE AP
WT 1 A 0 0
HT A 1 0 0
AGE 0 0 1 0
AP 0 0 0 1
Table 6.3 Correlation structure 3: two true covariates (WT and AGE). A
increased by 0.1 from 0 to 1, resulting in 10 values.
WT HT AGE AP
WT 1 A B 0
HT A 1 0 0
AGE B 0 1 0
AP 0 0 0 1
Table 6.4 Correlation structure 4: two true covariates (WT and AGE). A
increased by 0.1 from 0 to 1 and B decreased by 0.1 from 1 to 0
concurrently, resulting in 10 combinations.
6.2.3 Pharmacokinetic data simulation
The simulation followed the procedure described by Jonsson and Karlsson (1998). Ten data
sets were simulated with each data set containing 64 individuals. Half of the individuals were
sampled with 0.5, 2, 4 and 6 hours after dose and the other half were sampled with 0.5, 2, 8,
12 hours post-dose.
Drug concentration was simulated based on one compartment model i.v. bolus model using
NONMEM:
퐶푖푗 =
퐷표푠푒
푉푖
푒
−퐶퐿푖
푉푖
푡푖푗 (6.1)
For one true covariate (WT, sample mean: 85), we used the following model,
퐶퐿 = 휃1 + 휃2
푊푇
85
(6.2)
For two true covariates (WT and AGE, sample mean: 85 and 56 respectively), we used the
102
following model,
퐶퐿 = 휃1 + 휃2
푊푇
85
+ 휃3
퐴퐺퐸
56
(6.3)
For each A value or combination of A and B value, we repeated simulation for 10 times.
Thus, we got 100 data sets for each correlation structure, and 400 data sets for four correlation
structures. Figure 6.1 shows time versus concentration for four data sets (for correlation
structure 1 and 3, correlation between WT and HT is 0.1; for correlation structure 2 and
4, correlation between WT and HT is 0.1 and correlation between WT and AGE is 0.9).
Four scatterplots for concentration versus weight/height/age/alkaline phosphatase are shown
in Figure 6.2, Figure 6.3, Figure 6.4, and Figure 6.5 respectively. Two scatterplot matrices for
four correlation structures are shown in Figure 6.6 and Figure 6.7 respectively.
All data were ﬁtted with NONMEM using ﬁrst-order conditional method with interaction.
6.2.4 Covariate selection method
In this research, for the generalized additive model, we utilized R package, gam (Hastie,
2009), and built a GAM model in a step-wise fashion. For gradient boosting, we used the R
package, gbm (Ridgeway, 2007). For random forest, we used R package, randomForest (Liaw
and Wiener, 2002), to ﬁt the model. In all these methods, the parameter estimates (CL and
V) from NONMEM were used as the response variables and covariates were considered as
explanatory variables.
6.2.5 Performance measures
For GAM method, covariates selected by model were considered as true covariates. For
gradient boosting and random forest, the relative importance of predictor variables was con-
sidered as the criterion for screening covariates. The variables with highest score and highest
inﬂuence on response were considered as true covariates.
In 10 simulated data sets for each correlation structure, we performed covariate model
selection with these algorithms for 10 times. We used the times to identify true covariates
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Figure 6.1 Time versus concentration for four simulated data sets. For
correlation structure 1 and 3, correlation between WT and HT
is 0.1; for correlation structure 2 and 4, correlation between
WT and HT is 0.1 and correlation between WT and Age is
0.9. There is no clear diﬀerence among these four correlation
structures.
as the performance measures. For two covariates, if only one covariate was selected in some
simulated data set, 0.5 was assigned as the time to identify true covariates.
6.3 Results
6.3.1 Correlation structure of covariates
6.3.1.1 One true covariate (WT)
There were two correlation structures for one true covariate: correlation structure 1 (Ta-
ble 6.1) and correlation structure 2 (Table 6.2). The correlation structure 1 includes one
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Figure 6.2 Weight versus concentration for four simulated data sets. For
correlation structure 1 and 3, correlation between WT and HT
is 0.1; for correlation structure 2 and 4, correlation between WT
and HT is 0.1 and correlation between WT and Age is 0.9.
correlation between WT and HT. The times to identify the true covariate varied between 3
and 6 in Figure 6.8(left). When the correlation reached 0.9, GAM method only identiﬁed the
true covariate for two times in 10 data sets. The correlation structure 2 includes two corre-
lations, one between WT and HT, and the other between WT and AGE. For this correlation
structure, the times to identify the true covariate jumped to 8, then dropped to 4 and stayed
around 6 in Figure 6.8(right) when the correlation between WT and HT increased and the
correlation between WT and AGE decreased. In these two correlation structures and only one
true covariate, GAM method performed diﬀerently.
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Figure 6.3 Height versus concentration for four simulated data sets. For
correlation structure 1 and 3, correlation between WT and HT
is 0.1; for correlation structure 2 and 4, correlation between WT
and HT is 0.1 and correlation between WT and Age is 0.9.
6.3.1.2 Two true covariates (WT and AGE)
The accuracy of GAM method decreased when the correlation between WT and HT in-
creased for both correlation structure 3 and 4. For simple correlation structure 3 (correlation
between WT and AGE), the maximum times to identify correct covariates were 3.5 at corre-
lation 0.1 and the minimum times were 2 at correlation 0.6 in Figure 6.9(left). For complex
correlation structure 4 (correlations between WT and HT, WT and AGE), the maximum
times and minimum times were 4.5 at correlation 0.2, and 1.5 at correlation 0.9, respectively
in Figure 6.9(right).
GAM performed best in correlation structure 2 (Figure 6.10). In other three correlation
structures (1, 3 and 4), GAM performed similarly. The results had highest variability in
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Figure 6.4 Age versus concentration for four simulated data sets. For cor-
relation structure 1 and 3, correlation between WT and HT is
0.1; for correlation structure 2 and 4, correlation between WT
and HT is 0.1 and correlation between WT and Age is 0.9.
correlation structure 1.
6.3.2 Comparison of covariate selection methods
Three algorithms performed diﬀerently for four correlation structures. For correlation
structure 1, there was no obvious diﬀerence in three algorithms in Figure 6.11(left). However,
gradient boosting generated smallest variability among three algorithms (Figure 6.13). For
correlation structure 2, there was no diﬀerence in three algorithms in Figure 6.11(right), and
GAM had smallest variability (Figure 6.13). For correlation structure 3, gradient boosting and
random forest both performed better than GAM in Figure 6.12(left), and all three algorithms
generated similar variability to identify true covariates (Figure 6.13). For correlation structure
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Figure 6.5 Alkaline phosphatase versus concentration for four simulated
data sets. For correlation structure 1 and 3, correlation between
WT and HT is 0.1; for correlation structure 2 and 4, correlation
between WT and HT is 0.1 and correlation between WT and
Age is 0.9.
4, gradient boosting and random forest performed better than GAM in Figure 6.12(right).
Gradient boosting had smallest variability (Figure 6.13).
By comparing the combination of correlation structures and methods, Figure 6.13 shows
that for correlation structure 1 and 2, all three algorithms performed very similarly with some
diﬀerence in variability; for correlation structure 3 and 4, both gradient boosting and random
forest performed better than GAM.
6.4 Discussion
Contrary to our expectation, high correlation did not decrease accuracy of covariate selec-
tion for all three methods. Ribbing and Jonsson (Ribbing and Jonsson, 2004) discussed the
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Figure 6.6 Scatterplot matrix for correlation structure 1 and 3. Correlation
between WT and HT is 0.1. Conc: concentration. WT: weight.
HT: height. AP: alkaline phosphatase.
simple collinearity of covariates with one true covariate in 2004. They found that high corre-
lation hurts prediction power of true covariates. In that research, they only worked with one
true covariate, and in the ﬁeld of pharmacokinetic research, generally two to four covariates
were included in the model building. In this paper, we investigated more complex correlation
structures with one and two true covariates. Totally four covariates (age, weight, height and
alkaline phosphatase) had been selected in the simulation. Our results did not ﬁnd any relation
between high correlation and low accuracy of covariate selection. This may result from small
data sets we used in simulation.
Gradient boosting and random forest performs better than GAM when there are two true
covariates. GAM method was proposed by Mandema et al. (1992), and implemented in Xpose
(Jonsson and Karlsson, 1999). When the covariate correlation exists, GAM method has selec-
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Figure 6.7 Scatterplot matrix for correlation structure 2 and 4. Correlation
between WT and HT is 0.1 and correlation between WT and
Age is 0.9. Conc: concentration. WT: weight. HT: height. AP:
alkaline phosphatase.
tion bias issue. Semmar et al. (2005) applied hierarchical cluster analysis to combine single
covariate. By building a multivariate categorical covariate, they achieved a three-cluster model
with better performance than basic model. Xpose also includes a decision tree approach to
address this question. In this research, we took a new approach based on gradient boosting.
This method emphasizes “the committee of weak classiﬁers” to improve performance of trees,
and Hastie et al. (2009) announced this algorithm as the “best oﬀ-the-shelf classiﬁer in the
world”. The performance of random forest is quite similar to gradient boosting. As found
in Figure 6.13, these two alternative algorithms: gradient boosting and random forest work
better in covariate selection than GAM when there are two true covariates.
In this research, a few issues are not covered. First, we only used parameters as response
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variables for covariate selection. Wahlby et al. (2002) found that random eﬀect (ETA) is more
sensitive for covariate selection. As a continuation of this work, it will be more informative
to compare the diﬀerence of parameter, random eﬀect, and weighted residual as responsible
variables on covariate selection. In addition, we need to beware that the sample size is small
in this research. We only simulated 10 data sets for each correlation structure and with large
size of data, the selection methods may perform diﬀerently.
In a word, this paper focuses on the eﬀects of covariate correlation on covariate model
building. By investigating a series of correlation structures, we demonstrate that GAM is
not so sensitive to covariate selection no matter what covariate correlation exists though its
accuracy is not very high. In addition, we compare three related algorithms for covariate
selection based on EBE: GAM, gradient boosting and random forest. Gradient boosting and
random forest performs better than GAM when there are two true covariates. The comparison
of these three algorithms provides further direction for incorporating these two algorithms to
improve accuracy of this EBE-based method.
6.5 Conclusions
In this research, we focus on EBE-based method and explore the eﬀects of covariate
collinearity on covariate model building and compare performance of three algorithms, in-
cluding generalized additive model (GAM), gradient boosting and random forest. We found
that three algorithms perform similarly with one true covariate. When two true covariates
were in the model, gradient boosting and random forest perform better than GAM. In re-
gards of covariate correlation, GAM is more sensitive to correlation structure while the other
two algorithms perform consistently. This research reveals the performance diﬀerence of three
algorithms, and provides direction for improving accuracy of covariate selection.
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Figure 6.8 Covariate selection for one true covariate and correlation struc-
ture 1 and 2. X is the correlation between weight (WT) and
height (HT); Y is the times to identify the true covariate with
GAM method in 10 data sets. Left ﬁgure: the times to identify
the true covariate varied between 3 and 6. When the correlation
reached 0.9, GAM method identiﬁed the true covariate for only
two times in 10 data sets. Right ﬁgure: the times to identify
the true covariate jumped to 8, then dropped to 4 and stayed
around 6 when the correlation between WT and HT increased
and the correlation between WT and AGE decreased.
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Figure 6.9 Covariate selection for two true covariates and correlation struc-
ture 3 and 4. X is the correlation between weight (WT) and
height (HT); Y is the times to identify the true covariate with
GAM method in 10 data sets. Left ﬁgure: the maximum times
to identify correct covariates were 3.5 at correlation 0.1 and
the minimum times were 2 at correlation 0.6. Right ﬁgure: the
maximum times and minimum times were 4.5 at correlation 0.2,
and 1.5 at correlation 0.9, respectively.
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Figure 6.10 Comparison of performance of GAM in four correlation struc-
tures. X is correlation structure; Y is the times to identify the
true covariate with GAM method in 10 data sets. GAM per-
formed best in correlation structure 2. Correlation structure
1 resulted in highest variability.
114
Correlation
Ti
m
es
 to
 id
en
tif
y 
tru
e
 c
ov
a
ria
te
s 
(to
tal
: 1
0 d
ata
 se
ts)
0
2
4
6
8
corStructure 1
l
l
l l
l
l l l
l
l
l
l
l
l
l
l
l l
l
l
l l
0.2 0.4 0.6 0.8
corStructure 2
l
l
l
l
l
l
l
l l
l
l l
l
l
l l ll
l
l l
0.2 0.4 0.6 0.8
type
l gam
l gbm
l rf
Figure 6.11 Performance of three algorithms for covariate selection (cor-
relation structure 1 and 2). There was no obvious diﬀerence
in three algorithms for both left ﬁgure and right ﬁgure. gam:
generalized additive model; gbm: gradient boosting; rf : ran-
dom forest.
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Figure 6.12 Performance of three algorithms for covariate selection (corre-
lation structure 3 and 4). Gradient boosting and random forest
both performed better than GAM. gam: generalized additive
model; gbm: gradient boosting; rf : random forest.
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Combination of correlation structures and methods
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Figure 6.13 Performance of combination of correlation structures and
methods. For correlation structure 1 and 2, all three algo-
rithms performed very similarly with some diﬀerence in vari-
ability; for correlation structure 3 and 4, both gradient boost-
ing and random forest performed better than GAM. gam: gen-
eralized additive model; gbm: gradient boosting; rf : random
forest.
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CHAPTER 7. GENERAL CONCLUSION AND FUTURE WORK
7.1 Methodology
The main contributions of methodology in this thesis are the development of PopPK model
diagnostics, described as follows:
∙ Interactive graphics is applied to model building, including the exploratory data analysis,
goodness of ﬁt, model validation and model comparison. This is a new addition to the
practice of PopPK modeling. It provides a more systematic evaluation of these relatively
complicated models.
∙ New visual methods have been developed to examine resampling statistics for PopPK
modeling. Resampling statistics arise when multiple models are ﬁt. The parameter es-
timates and ﬁt diagnostics are extracted and results are visualized. This work expands
the ability to diagnose PopPK models by visualizing resampling statistics. Visual meth-
ods from multivariate analysis, parallel coordinate plots and multidimensional scaling,
are applied to create the new visualizations. The resampling statistics need to be care-
fully re-scaled. The visual methods help the analyst understand the eﬀect of individual
patients on the model, and dependencies between patients and parameter estimates.
∙ Preliminary work on exploring the eﬀects of correlation structure on covariate selection
in PopPK modeling has been performed. Three algorithms for identifying the best co-
variates are compared.
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7.2 Software
To help users utilize the methods developed in this thesis for PopPK model diagnostics, I de-
veloped two R packages, PKgraph and PKreport. PKgraph source code is distributed through
http://cran.r-project.org/web/packages/PKgraph/index.html. PKreport is available at
http://pkreport.sourceforge.net/.
7.2.1 PKgraph
This package is a graphical user interface for diagnosing PopPK models in R. It reads in
results from other specialist modeling software and provides the methods necessary to diag-
nose the models using the methods described in the previous section. PKgraph can generate
high-quality ﬁgures for FDA submission, using the R graphics packages, lattice and ggplot2.
Furthermore, plots for exploratory data analysis, goodness of ﬁt, model validation and model
comparison can be linked using interactive graphics, enabling deeper inspection of dependencies
and correlations. The resampling statistics can be visualized. The PKgraph package serves as
a supplement to the existing software, NONMEM, Monolix, SAS NLMIXED, R nlme, Xpose
and PsN, used for ﬁtting models and generating resampling statistics.
7.2.2 PKreport
This package generates automated diagnostics for model assumption testing. It is designed
based on the current working procedures of PopPK analysts, who prefer to have a large col-
lection of plots generated automatically with a model ﬁt. It also uses the R graphics packages,
lattice and ggplot2, and can generate high-quality ﬁgures for the FDA, archive all ﬁgures with
speciﬁc folders for report and review, and utilize a web browser as the interface for viewing,
archiving and analyzing.
7.3 Future work
The main contribution of this thesis has been to develop methods and software for diag-
nosing PopPK models. There are some obvious next steps for the research.
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First, testing these methods and software on real data is vital. The software needs to be
used in the pharmaceutical industry to assess its usefulness, and determine the direction of the
development.
Second, PKgraph is based on rggobi for interactive graphics, and rggobi is not so ﬂexible to
be integrated with the whole system. The next step would be to incorporate a new R package:
qtpaint (qtinterfaces project group, 2009) to replace rggobi and provide a more ﬂexible and
faster working environment. qtpaint is not in a state that can be used at this stage of the
research, but it hopefully will be available in the coming year.
Third, the work on covariate selection with three algorithms, GAM, gradient boosting and
random forest, is preliminary. The parameters were treated as response variables for covariate
selection. Further work would compare the diﬀerences of the parameter, random eﬀects, and
weighted residual as response variables being considered in the covariate selection.
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APPENDIX A. USER GUIDE FOR PKGRAPH PACKAGE
Introduction
Population pharmacokinetic (PopPK) modeling has become increasing important in drug
development because it allows unbalanced design, sparse data and the study of individual
variation. However, this complexity of the model makes it a challenge to diagnose the ﬁt.
Graphics can play an important and unique role in PopPK model diagnostics. The software
described in this paper, PKgraph, provides a graphical user interface for PopPK model di-
agnosis with interactive graphics. It also provides an integrated and comprehensive platform
for analysis of pharmacokinetic data including exploratory data analysis, goodness of model
ﬁt, model validation and model comparison. It can be used with a variety of modeling ﬁtting
software, including NONMEM, Monolix, SAS and R. PKGraph is programmed in R, and uses
the R packages lattice, ggplot2 for static graphics, and rggobi for interactive graphics. This
R package is supported with a user-friendly graphical user interface so that users can easily
control diagnosing with simple clicks. The PKGraph software serves as a supplement to the
existing packages: NONMEM, Xpose and PsN for diagnosing models.
PKgraph is an R packaged built on the following R packages: RGtk2, gWidgets, gWid-
getsRGtk2, lattice, and ggplot2. It requires R (> 2.0) and GTK+, and runs under Windows,
Linux and Mac.
Installation
PKgraph needs to install the following programs and R packages:
1. install GTK
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For Windows, you can download the GTK Developer’s Pack from
http://gladewin32.sourceforge.net/
For Unix, you can fetch the source ﬁles for the diﬀerent libraries from
ftp://ftp.gtk.org/pub/gtk/v2.8/
2. Install RGtk2 (Please see RGtk2 Installation notes if you have problems) (Lawrence and
Temple Lang, 2009)
a. Install R package, RGtk2: install.packages(“RGtk2”)
3. install rggobi (Temple Lang et al., 2009)
a. Download and install ggobi (www.ggobi.org)
b. Install rggobi: install.packages(“rggobi”)
4. Install gWidgets (on the iwidgets code of Simon Urbanek et al., 2009)
a. Install R package, gWidgets: install.packages(“gWidgets”)
5. Install gWidgetsRGtk2 (Lawrence and Verzani, 2010)
a. Install R package, gWidgetsRGtk2: install.packages(“gWidgetsRGtk2”)
6. Install lattice (Sarkar, 2008)
a. Install R package, lattice: install.packages(“lattice”)
7. Install ggplot2 (Wickham, 2009)
a. Install R package, lattice: install.packages(“ggplot2”)
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PKgraph infrastructure
The software incorporates a key concept: interactive graphics to link various datasets and
diagnostics plots. The framework is programmed using RGtk2 and consists of main formats of
interfaces, (1) main, containing links to all parts of the software, and handles the basic data
management, and links to diagnostic modules, and (2) graph, which provides tools speciﬁcally
for each diagnostic module. (2). Basic module: data input/output module, conﬁguration
module, and data management module.
Graphical user interfaces
Main interface
The main interface (Figure A.1) of PKgraph provide the links to all components of the
software. There are four areas: (1) tool area (tool bar and menu bar, top), (2) directory area
(middle-left), (3) data area (middle-right) and (4) status bar (bottom).
∙ The tool area has menu items linking to the basic management modules (project, con-
ﬁguration, data management) and the diagnostic modules (exploratory data analysis,
PK models, model validation, model comparison and interactive diagnostics). These are
menu items containing numerous functions associated with each of the diﬀerent types of
diagnostics.
∙ The directory area shows current directory and all of its ﬁles. These ﬁles might be data
ﬁles, or code, depending on the modeling software used.
∙ Clicking on any of the data ﬁles, will open them and display them in the data area (3).
Choosing the ﬁle also brings up a panel allowing for diﬀerent formats to be read, thus
handling all possible modeling software formats. The data ﬁles might contain raw data,
and model diagnostics such as parameter estimates, ﬁtted values and residuals and these
are displayed in the table view of the data area.
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∙ The status bar displays the progress of the diﬀerent functions, for example here it says
“Data is loaded successfully” to indicate that there were no problems with opening the
data ﬁle.
1
2 3
4
Figure A.1 Main interface of PKgraph
Graph interface
Selecting an item from a diagnostic module menu brings up a graph interface (Figure A.2).
The style of the interface is the same for all diagnostic functionality. It contains three areas:
1) parameter setup area, 2) tool bar, 3) plot area.
∙ The parameter area setup allows choice of variable, plot labels, layout for trellis or
facetted plots. A choice of lattice or ggplot2 graphics is provided.
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∙ The tool bar allows the plots to be saved, opening the plot in ggobi for interaction on
the plot, synchronize subset selection from ggobi to the data in R, and close ggobi.
∙ The plot area displays the ﬁgure, and multiple ﬁgures if more than one are created.
1
2
3
Figure A.2 Graph interface of PKgraph
Functional module
Functional module matches the menu items in PKgraph toolbar. It includes the following
menu items:
∙ Project
∙ Conﬁgure
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∙ Data management
∙ Exploratory data analysis
∙ PK models
∙ Model validation
∙ Model comparison
∙ Interactive graphics
In the next sections, I will go through each menu item in detail.
Functions
In this section, I will go through each function in the menu item of toolbar.
Project
This menu item is in charge of input, output and save data. It has the following functions
(Figure A.3),
∙ Open data: open modeling ﬁt result from NONMEM, Monolix, SAS, R or other software.
It has options to setup the data format, start line and separation symbol.
∙ Save a ﬁle: save a ﬁle.
∙ Save a workspace: save a workspace for later usage. It generally saves a group of lists
for conﬁguration and related data.
∙ Restore old workspace: restore the workspace from the data and list you saved from
previous step.
∙ Exit : exit from PKgraph.
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Figure A.3 Menu items in Project
Conﬁgure
This menu item is utilized to conﬁgure PKgraph. It has the following functions (Fig-
ure A.4),
∙ Set working directory : change current directory.
∙ Set saving format : set up saving format for ﬁgures, including pdf, jpg, tiﬀ, png bmp,
win.metaﬁle, and ﬁgure width and height. If ﬁgure width and height is not setup, a
default one will be used.
∙ Save a workspace: save a workspace for later usage. It generally saves a group of lists
for conﬁguration and related data.
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∙ Set ﬁgure conﬁguration: color and loess can be setup here for ﬁgures.
Figure A.4 Menu items in Conﬁgure
Data management
This menu item is utilized to manage data. It has the following functions (Figure A.5),
∙ Subset : subset current data.
∙ Factor : factor categorical variables. Graphical packages require variables to be factor
type in order to display related symbol in ﬁgures.
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Figure A.5 Menu items in Data management
Exploratory data analysis
This menu item is utilized to explore data and screen patterns. It has the following functions
(Figure A.6),
∙ Univariates: plot univariate variables.
∙ Bivariates: plot bivariate variables.
∙ Parallel coordinate plot : Parallel coordinate plot for multivariate variables.
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Figure A.6 Menu items in Exploratory data analysis
Univariate
When clicking this menu item, users will generate a “graph interface”(Figure A.2). In this
interface, users can specify all parameters in the left area of window. In the right area of
window, it has the following four buttons on the top:
∙ save: save ﬁgures.
∙ ggobi : open the plot in ggobi for interaction on the plot.
∙ synchronize: synchronize subset selection from ggobi to the data in R.
∙ close: close ggobi.
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Bivariate
This menu item also generates a “graph interface”. It is similar to the Univariate interface,
except that users will have two variables instead of one.
Parallel coordinate plots
This menu item provides access to lattice function: parallel function from lattice package.
PK models
This menu item is utilized to check model assumptions and goodness of ﬁt. The guideline
follows Census menu (http://census.sourceforge.net/). It has the following functions (Fig-
ure A.7),
∙ Conﬁgure model result : This is the key step to match data variables to default metric
system. By this step, data from any platform (NONMEM, Monolix, SAS, R) can be
interpreted graphically in ﬁgures.
∙ Individual plots: Bivariate plot for each individual.
∙ Goodness of ﬁt plots: Goodness of ﬁt plot is one of key tools to check model ﬁtting.
These kinds of plots will give an overall perspective of model performance, including
scatter plot for concentration versus PRED, concentration versus IPRED, PRED versus
time and IPRED versus time.
∙ Parameters: Generally, there are assumptions for distribution of parameters during mod-
eling process. The histogram is utilized to check this distribution. In addition, the
correlation of parameters has signiﬁcant eﬀect on modeling performance, and it can be
checked by scatter plots or a scatterplot matrix.
∙ Random eﬀects: The assumptions for random eﬀects also need to be tested for distribu-
tion and correlation by histogram, scatter plots or a scatterplot matrix.
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∙ Structural model : Structural model can be diagnosed by PRED versus concentration con-
ditioned on time, IPRED versus concentration conditioned on time, WRES versus time,
WRES versus PRED, PRED versus concentration conditioned on covariates, IPRED
versus concentration conditioned on covariates.
∙ Residual error model : Two assumptions are related to this submodel: 1) homoscedastic
variability; 2) symmetrically distributed residuals. To test these assumptions, we applied
the following techniques: 1) histogram for distributions of WRES; 2) histogram for indi-
vidual distribution of WRES; 3) scatterplot of ∣WRES∣ versus PRED to check the shape
of residual; 4) scatterplot of ∣WRES∣ versus PRED conditioned on covariates to screen
the covariate eﬀects; 5) autocorrelation of WRES.
∙ Covariate model : Parameters, ETA and WRES are of great use to help screen proper
covariates. We can utilize the following methods to check covariate models: 1) scatter
plot for parameters versus covariates, ETAs versus covariates, WRES versus covariates;
2) scatterplot matrix of covariates.
Users have to conﬁgure data variable ﬁrst before going to speciﬁc model diagnostics. To
illustrate the usage of this menu item, I will use Conﬁgure model result and Parameters as
examples.
Conﬁgure model result
The interface for this function is shown in Figure A.8. The ﬁxed variables are from data,
and the ﬂexible variables are from default metric system (Table A.1).
Parameters
The interface for this function is shown in Figure A.9. After users choose proper ﬁgures
in the left window, the system will produce all ﬁgures automatically. Users can pick speciﬁc
ﬁgures for diagnosing with functions in the toolbar.
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Figure A.7 Menu items in PK models
Model validation
Resampling methods has been extensively employed in the model validation. Currently,
bootstrap targets for conﬁdence interval, case deletion diagnostics identify inﬂuential cases,
and stochastic simulation is utilized to compare models (PsN). PKgraph mainly focuses on
case deletion diagnostics and bootstrap. It provides the following functions (Figure A.10),
∙ Inﬂuence analysis summary (PsN): analyze PsN cdd results.
∙ Visualization for inﬂuence analysis: apply parallel coordinate plots and multidimensional
scaling to visualize data from case deletion diagnostics (multiple NONMEM runs).
∙ Bootstrap summary (PsN): analyze PsN boot results.
∙ Visualization for bootstrap: visualize data from bootstrap (multiple NONMEM runs).
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Figure A.8 Conﬁgure model result in PK models
Inﬂuence analysis summary (PsN)
This function is speciﬁcally for PsN cdd results (Figure A.11). It takes two result ﬁles from
PsN: raw results1.csv and skipped individuals1.csv, and generates a scatter plot for cov.raito
versus cov.score.
Visualization for inﬂuence analysis
This function is to visualize data from case deletion diagnostics (multiple NONMEM runs).
Let’s use multiple NONMEM run form PsN (Figure A.12), and ﬁnd ﬁle directory for these
runs. Then we can select parameters as shown in Figure A.13. These parameters include:
∙ Target directory path: the path for multiple NONMEM runs. It is a required parameter.
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Package variable Description
ID Patient ID
TIME Time after dose
CONC The concentration of drug in the body
PRED Prediction generated from model ﬁtting
RES Residual
WRES Weighted residual
IPRED Individual prediction
IWRES Individual weighted residual
COV Covariates
Table A.1 Package metric system
∙ Simulation folder pattern: the common name style for multiple NONMEM runs. For
this example, it is NM run. It is a required parameter.
∙ Patient ID : the ID for each subject. It is a required parameter.
∙ Plot variable: the variable you use to detect diﬀerence among patients. For this example,
we choose CL. It is a required parameter.
∙ xlabel : the name label for each NONMEM run. It is optional.
Bootstrap summary (PsN)
This function is speciﬁcally for PsN boot results (Figure A.14). It takes two result ﬁles
from PsN: raw results1.csv and included individuals1.csv, and generates related plots.
Visualization for bootstrap
This function is to visualize data from boostrap (multiple NONMEM runs). Let’s use
multiple NONMEM run form PsN (Figure A.15), and ﬁnd ﬁle directory for these runs. Then
we can select parameters as shown in Figure A.16. These parameters include:
∙ Target directory path: the path for multiple NONMEM runs. It is a required parameter.
∙ Bootstrap folder pattern: the common name style for multiple NONMEM runs. For this
example, it is NM run. It is a required parameter.
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Figure A.9 Parameters in PK models
∙ NONMEM result ﬁle name: the ﬁt result for each NONMEM run. In this example, it is
CS1 IV1ESTFPDF-1.ﬁt . It is a required parameter.
∙ Bootstrap key table path: the path for bootstrap key ﬁle, which is ﬁle describing the
sampling schema for patient IDs. It is a required parameter.
∙ Bootstrap key table name: The ﬁle describes the sampling schema for patient IDs In this
example, it is included individuals1.csv. It is a required parameter.
∙ Patient ID : the ID for each subject. It is a required parameter.
∙ Plot variable: the variable you use to detect diﬀerence among patients. For this example,
we choose CL. It is a required parameter.
∙ xlabel : the name label for each NONMEM run. It is optional.
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Figure A.10 Menu items in Model validation
Model comparison
In this process, there are three main steps: 1) select datasets; 2) conﬁgure mapping; 3)
comparison (Figure A.17). The ﬁrst step is to select datasets for comparison. Currently the
program only supports comparison of two models. Then users proceed to conﬁgure mapping
by matching column names or variable names from two data sets. These matching variables
are generally the variables from original data sets and they are not related to model ﬁtting.
When all parameters are set, the program oﬀers three choices for comparison: “histogram com-
parison” (distribution comparison), “scatter plot comparison” and “transform comparison”.
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Figure A.11 Inﬂuence analysis summary (PsN)
Select datasets
This function is to select datasets available in the PKgraph data area. Figure A.18 shows
there are three data sets available, including ﬁt result 2: 2 CS1 IV1ESTFPDF.ﬁt (ﬁt with
additive error model) and ﬁt result 3: 3 CS1 IV1ESTFPDF.ﬁt2 (proportional error model).
In this example, we will compare these two models.
Conﬁgure mapping
This step will join two ﬁt results. As a result, users have to match the original data variables
between two ﬁt results. For example (Figure A.19),
∙ Matching variables: ID, Time, Concentration, WT, AGE, etc must be matched in this
step. These variables do not change with diﬀerent models.
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Figure A.12 Multiple NONMEM runs for case deletion diagnostics
∙ Non-matching variables: RES, PRED, WRES, etc are ﬁt results, and should NOT be
matched. These variables change with diﬀerent models.
After mapping, a new dataset joining two ﬁt results will show in data area of main interface.
Comparison
“histogram comparison” enables to compare distributions of matching parameters from two
models. “scatter plot comparison” provides a environment to compare matching parameters by
scatter plot. “transform comparison” transforms data by ratio or log ratio in order to visualize
the diﬀerence between variables from two models. All these models can be linked directly to
ggobi for interactive diagnostics by clicking second button in the tool bar area on the top right
panel.
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Figure A.13 Parameters and results for case deletion diagnostics
All variable names for model 1 will have additional “.x” label, and all variable names for
model 2 will have additional “.y” label.
Let us look at “histogram comparison” as one example. First, we need to make sure
that current data set is “4 ModelComparison” (Figure A.20); second, we click “histogram
comparison”. To compare CL, we select ISM (gender) as the conditional variable, and the
result is shown in (Figure A.21).
Interactive graphics
This functional module incorporates a unique feature: interactive graphics into every step
of model diagnostics. It targets to link diverse data sets in one integrative platform. Users
can have access to this feature through ggobi button in the graph interface. In addition, users
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Figure A.14 Bootstrap summary (PsN)
have ﬂexibility to apply this feature to achieve their speciﬁc goals. In the toolbar, there is
option: interactive graphics, designed for this purpose. It includes three steps: select datasets;
conﬁgure mapping; and diagnostics. By linking diverse data sets with a key variable, users can
seek patterns by brushing, linking and diagnosing patterns conveniently.
Example
One dataset from NONMEM is utilized to demonstrate PKgraph. This data set has 100 pa-
tients with covariates: ISM (gender), AGE, and WT. The data is ﬁtted with one compartment
model with zero order absorption and ﬁrst order elimination.
As a text ﬁle, the ﬁtting result from NONMEM is imported into PKgraph for further
investigation and analysis. In the “open” dialog, we set up ﬁle format for reading with default
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Figure A.15 Multiple NONMEM runs for bootstrap
parameters, and as a result, the input data shows up on the right panel while a message, “Data
is loaded successfully” appears in the status bar at bottom of panel.
To further explore data, ﬁrst, we choose “Bivariates” from “Exploratory Data Analysis”
located at menu bar to check the scatter plots of interested variables (Figure A.22, Figure A.23).
The option “cond” from the functional model interface helps user to draw conditional plots
to seek patterns for subgroups. Certainly, users can also select “ggplot2” graphic package
with diﬀerent taste of ﬁgure. Next, we can take advantage of interactive techniques to look at
maximum concentration by clicking second image button on the right panel. This will start
ggobi and load related data. GGobi includes two windows: console window and plot window.
In order to link ﬁgures together, users need to open all interested ﬁgures by “Display” option
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Figure A.16 Parameters and results for bootstrap visualization
in the menu bar. The following ﬁgure clearly shows that maximum concentration comes from
male patients (value: 1). To look at these data in detail, we go back to the ﬁgure graphical
user interface and click third image button to check selected data set in ggobi. The selected
data set pops up and links to patient with ID: 55. We repeat the same procedure for other
variables to check patterns.
Next, we utilize “PK model” option to check model assumptions and diagnose model ﬁtting.
The program provides default names such as ID, TIME, COV, etc in order to automatically
generate diagnosing results. After we match data variables to the default names, we can
proceed to automatically generate routine goodness of ﬁt plots for interested models. Figure
A.24 is one of the results for structural model diagnostics.
To further look at the inﬂuential cases from same data set, we can link them together by
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Figure A.17 Menu items in Model comparison
“model validation” option in menu bar. In this process, we have 100 NONMEM runs available
at directory: C:∖ Projects∖modelﬁt dir1 using PsN function: cdd. Let’s input the path of these
NONM runs, and select plot variable as “CL”. After clicking “OK”, we will have the parallel
coordinates plot showing the CL variables for all NONMEM runs. From Figure A.25, we can
see some patients have more inﬂuential eﬀects on CL when records from these patients are
deleted.
Let’s identify these inﬂuential cases with interactive graphics. Figure A.26 clearly demon-
strates that these inﬂuential cases come from patient 52 and 20 based on multidimensional
scaling and parallel coordinate plots.
In addition, we compare additive error model (2 CS1 IV1ESTFPDF.ﬁt) with proportional
error model (3 CS1 IV1ESTFPDF.ﬁt2) by “model comparison” function in the menu bar.
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Figure A.18 Select datasets in Model comparison
By comparing the distribution of two models, Figure A.27 does not ﬁnd signiﬁcant diﬀerence
between two models for CL. In addition, using gender as a conditional variable, we found ﬁrst
model always gave a higher peak value for both male and female.
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Figure A.19 Conﬁgure mapping in Model comparison
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Figure A.20 Current data set for Model comparison
147
Figure A.21 histogram comparison for Model comparison
148
Figure A.22 Exploratory data analysis. Peak is identiﬁed with brushing.
This patient is from light weight and middle age group.
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Figure A.23 Exploratory data analysis. The detailed information for this
patient is selected for investigation.
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Figure A.24 Structural model diagnostics.
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Figure A.25 Inﬂuence analysis
152
Figure A.26 Inﬂuence analysis: linking results from multidimensional scal-
ing and parallel coordinate plots.
153
Figure A.27 Histogram comparison for comparing distributions of CL from
two models.
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